

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/560,891	TANAKA ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	David K. O'Dell	1609	

**All Participants:**

(1) David K. O'Dell.

(2) Mr. Michael R. Davis.

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_.

(4) \_\_\_\_\_.

**Date of Interview:** 18 May 2007

**Time:** 11:00 A.M.

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

Claims discussed:

1

Prior art documents discussed:

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*The examiner discussed withdrawal of restriction requirement between groups I-III, and amendments to claim 1. No resolution was reached at that time, however applicant's representative wanted to have consultation with client and discuss further.*

**Part III.**

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

## Interview Summary

**Application No.**

10/560,891

**Applicant(s)**

TANAKA ET AL.

**Examiner**

David K. O'Dell

**Art Unit**

1609

All participants (applicant, applicant's representative, PTO personnel):

(1) David K. O'Dell.

(3)\_\_\_\_\_.

(2) Michael R. Davis.

(4)\_\_\_\_\_.

Date of Interview: 21 May 2005.

Type: a) ☒ Telephonic b) ☐ Video Conference

c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.

If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 1.

Identification of prior art discussed: \_\_\_\_\_.

Agreement with respect to the claims f) ☒ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

\_\_\_\_\_  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The applicant responded to the examiner's request as per claim amendments on the interview of 5/18/07, and details of such amendments were discussed, particularly the identity of n in claim 1 and various substituents R#'s. Applicant submitted claims (B-2) that needed only minor typographical corrections. The applicant stated that consultation with the inventor was required, after which an amended claim set was submitted with claim amendments making the claims commensurate in scope as per the discussion. The examiner would like to note on the record that applicant's representative Mr. Davis was very professional and patient throughout the entire process.

## Summary of Record of Interview Requirements

### Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

### Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

### 37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,  
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.


### Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.



Amendments to the Claims


1. (Currently amended) An epoxy compound of formula (1):




wherein n represents an integer of 1 to 9 4,

the  $-(CH_2)_n-$  group may have inserted  $-O-$ , ~~or  $-N(R^2)-$~~  between the methylene groups, wherein  ~~$R^2$  represents a hydrogen atom or a  $C_{1-18}$  alkyl group;~~

Z represents any one of divalent groups of the following general formulas (Z-1) to ~~(Z-6)~~ (Z-3):




wherein  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9$  and  $R^{10}$ .  $R^5$  and  $R^6$  are the same or different and represent independently a hydrogen atom, ~~a  $C_{1-18}$  alkyl group, an amino group substituted with one or two  $C_{1-18}$  alkyl groups, or a cyclic amino group of the following formula:~~




wherein  $m$  represents an integer of 4 to 12, and one methylene group or two or more not neighboring methylene groups of the  $C_{1-12}$  alkyl group or groups as defined in connection with  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9$  or  $R^{10}$ , and of the cyclic amino group, may be replaced with  $O$ ,  $NH$ ,  $N(R^{11})$  or  $S$ , wherein  $R^{11}$  represents a  $C_{1-12}$  alkyl group, atom or a  $C_{1-12}$  alkyl group.


$Ar^1$  and  $Ar^2$  are the same or different and represent any one of groups is a group of the following formulas (A-1) to (A-3) formula (A-1), and  $Ar^2$  is a group of the following formula (A-1) or (A-3):



(A-1)




(A-2)



(A-3)


wherein  $A$  represents a single bond and or any one group selected from the group consisting of:



wherein  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$  and  $R^{22}$   $R^{20}$  and  $R^{21}$  are the same or different and represent independently a hydrogen atom, a halogen atom, a  $C_{1-8}$ -alkyl- $C_{1-4}$  alkyl group, a  $C_{1-8}$  alkoxy group, a cyano group, or a nitro group,


$Y^1$  and  $Y^2$  are the same or different and each represent a single bond, -O-, -S-, or  $-Si(R^{23})(R^{24})-$  wherein  $R^{23}$  and  $R^{24}$  are the same or different and represent independently a lower alkyl group or a phenyl group.

2. (Original) The epoxy compound according to claim 1, wherein  $Ar^1$  and  $Ar^2$  in formula (1) are the same or different and represent independently a group of the following formula:



wherein  $R^{25}$ ,  $R^{26}$ ,  $R^{27}$  and  $R^{28}$  are the same or different and represent independently a hydrogen atom or a methyl group.

3. (Original) The epoxy compound according to claim 1, wherein  $Ar^1$  and  $Ar^2$  in formula (1) represent the same group of the following formula:



wherein  $R^{25}$ ,  $R^{26}$ ,  $R^{27}$  and  $R^{28}$  are the same or different and represent independently a hydrogen atom or a methyl group.

4. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 1 and a curing agent.

5. (Original) The epoxy composition according to claim 4, wherein the curing agent is an amine-type curing agent or a phenol type curing agent.

6. (Previously presented) A cured epoxy resin product obtained by curing the epoxy composition as defined in claim 4.
7. (Previously presented) A prepreg obtained by impregnating or coating a substrate with the epoxy composition of claim 4 and then semi-curing the epoxy composition.
8. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 2 and a curing agent.
9. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 3 and a curing agent.
10. (Previously presented) A cured epoxy resin product obtained by curing the epoxy composition as defined in claim 5.
11. (Previously presented) A prepreg obtained by impregnating or coating a substrate with the epoxy composition of claim 5 and then semi-curing the epoxy composition.

Michael R. Davis  
Matthew M. Jacob  
Warren M. Cheek, Jr.  
Nils E. Pedersen  
Charles R. Watts  
Michael S. Huppert  
Jeffrey R. Filipek  
W. Douglas Hahn

David M. Ovedovitz  
Joseph M. Gorski\*  
Jonathan R. Bowser\*  
Jay F. Williams\*  
Amy E. Pulliam\*  
Kenneth Fields\*  
Carl Pledger\*

OF COUNSEL:  
John T. Miller

## WENDEROTH, LIND & PONACK, L.L.P.

*Attorneys and Counselors at Law*  
*Patents, Trademarks and Copyrights*  
2033 K Street, N.W., Suite 800  
Washington, D. C. 20006-1021 U.S.A.

E. F. Wenderoth (1886-1974)  
John E. Lind (1892-1983)  
A. Ponack (1900-1969)

TELEPHONE:  
202-721-8200

FACSIMILE:  
202-721-8250 (G-II)  
202-833-3015 (G-IV)

E-MAIL:  
wlp@wenderoth.com

INTERNET:  
www.wenderoth.com

### FACSIMILE COVER SHEET

\*Member of Bar other than D.C.

DATE: June 5, 2007

TO: Examiner David K. Odell/Rita Desai  
Group Art Unit 1609

Fax No.: (571) 273-0684

Confirmation No. 3651

FROM: Michael R. Davis 

Number of pages being transmitted, including this cover sheet: 9

Please direct all questions concerning the transmittal of these pages to Patricia Hill.

RE: Serial No. 10/560,891 (Shinya TANAKA et al. ), filed January 20, 2006

---

#### MESSAGE:

Referring to our recent telephone discussions/voicemails, I am enclosing a formal Supplemental Preliminary Amendment adopting all of the changes that we agreed upon.

#### CONFIDENTIALITY NOTICE

This message is intended for the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient or the agent responsible for delivering the message to the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us at the above address via the U.S. Postal Service.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of	:	<b>Confirmation No. 3651</b>
Shinya TANAKA et al.	:	Attorney Docket No. 2005_1857A
Serial No. 10/560,891	:	Group Art Unit 1609
Filed January 20, 2006	:	Examiner David K. Odell
EPOXY COMPOUND AND CURED EPOXY RESIN PRODUCT	:	<b>Mail Stop Amendment</b>

---

**SUPPLEMENTAL PRELIMINARY AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEE FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975.

Sir:

Kindly amend the above-identified application as follows:

**Amendments to the Specification**

**Page 18, please replace the paragraph spanning line 9 through page 19, line 6 with the following rewritten paragraph:**


The reaction of the alcohol compound (2) with the compound (3) is carried out generally by mixing both compounds in a solvent in the presence of a base, and said mixing may be conducted in an optional order. The solvent that may be used is not particularly limited as far as it is inert to the reaction, but from a viewpoint of easy suppression of byproduct formation, a hydrophilic solvent is preferable. Examples of the hydrophilic solvent include alcohol type solvents such as methanol, ethanol, propanol, butanol, ethylene glycol, and propylene glycol, ketone type solvents such as methyl ethyl ketone or methyl isobutyl ketone, non-protonic polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, or N-methylpyrrolidone, ether type solvents such as tetrahydrofuran, dioxane, methoxymethyl ether, or diethoxyethane, and mixtures thereof. Inter alia, ether type solvents, ~~non-protonic~~ aprotic polar solvents, and a mixture thereof are preferable. ~~Non-protonic~~ Aprotic polar solvents are more preferable and, inter alia, dimethyl sulfoxide is particularly preferable. An amount of the solvent that may be used is generally 0.1 to 50 parts by weight, preferably 0.5 to 5 parts by weight per part by weight of the alcohol compound (2).

**Page 21, please replace the paragraph spanning line 24 through page 22, line 4 with the following rewritten paragraph:**

After ~~oxidation~~ cyclooxidation by the oxidizing agent, the remaining oxidizing agent is decomposed if necessary, followed by concentration, to separate the epoxy compound (1). The separated epoxy compound (1) may be further purified by a conventional purification means, for example, by recrystallization.

Amendments to the Claims


1. (Currently amended) An epoxy compound of formula (1):



wherein n represents an integer of 1 to 9 4,


the  $-(CH_2)_n-$  group may have inserted  $-O-$ , ~~or  $-N(R^2)-$~~  between the methylene groups, wherein  ~~$R^2$  represents a hydrogen atom or a  $C_{1-18}$  alkyl group;~~

Z represents any one of divalent groups of the following general formulas (Z-1) to ~~(Z-6)~~ (Z-3):




wherein  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9$  and  $R^{10}$ .  $R^5$  and  $R^6$  are the same or different and represent independently a hydrogen atom, a  $C_{1-18}$  alkyl group, an amino group substituted with one or two  $C_{1-18}$  alkyl groups, or a cyclic amino group of the following formula:






wherein  $m$  represents an integer of 4 to 12, and one methylene group or two or more not neighboring methylene groups of the  $C_{1-12}$  alkyl group or groups as defined in connection with  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9$  or  $R^{10}$ , and of the cyclic amino group, may be replaced with  $O$ ,  $NH$ ,  $N(R'')$  or  $S$ , wherein  $R''$  represents a  $C_{1-12}$  alkyl group, atom or a  $C_{1-12}$  alkyl group.


$Ar^1$  and  $Ar^2$  are the same or different and represent any one of groups is a group of the following formulas (A-1) to (A-3) formula (A-1), and  $Ar^2$  is a group of the following formula (A-1) or (A-3):



(A-1)




(A-2)



(A-3)


wherein  $A$  represents a single bond and ~~or any one group selected from the group consisting of:~~



wherein  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$  and  $R^{22}$ ,  $R^{20}$  and  $R^{21}$  are the same or different and represent independently a hydrogen atom, a halogen atom, a  $C_{1-8}$  alkyl,  $C_{1-4}$  alkyl group, a  $C_{1-8}$  alkoxy group, a cyano group, or a nitro group,


$Y^1$  and  $Y^2$  are the same or different and each represent a single bond,  $-O-$ ,  $-S-$ , or  $-Si(R^{23})(R^{24})-$ , wherein  $R^{23}$  and  $R^{24}$  are the same or different and represent independently a lower alkyl group or a phenyl group.

2. (Original) The epoxy compound according to claim 1, wherein  $Ar^1$  and  $Ar^2$  in formula (1) are the same or different and represent independently a group of the following formula:



wherein  $R^{25}$ ,  $R^{26}$ ,  $R^{27}$  and  $R^{28}$  are the same or different and represent independently a hydrogen atom or a methyl group.

3. (Original) The epoxy compound according to claim 1, wherein  $Ar^1$  and  $Ar^2$  in formula (1) represent the same group of the following formula:



wherein  $R^{25}$ ,  $R^{26}$ ,  $R^{27}$  and  $R^{28}$  are the same or different and represent independently a hydrogen atom or a methyl group.

4. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 1 and a curing agent.

5. (Original) The epoxy composition according to claim 4, wherein the curing agent is an amine-type curing agent or a phenol type curing agent.

6. (Previously presented) A cured epoxy resin product obtained by curing the epoxy composition as defined in claim 4.

7. (Previously presented) A prepreg obtained by impregnating or coating a substrate with the epoxy composition of claim 4 and then semi-curing the epoxy composition.

8. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 2 and a curing agent.

9. (Previously presented) An epoxy composition, which comprises the epoxy compound as defined in claim 3 and a curing agent.

10. (Previously presented) A cured epoxy resin product obtained by curing the epoxy composition as defined in claim 5.

11. (Previously presented) A prepreg obtained by impregnating or coating a substrate with the epoxy composition of claim 5 and then semi-curing the epoxy composition.

### Remarks

#### Substance of Interview

During a telephone discussion with the Examiner on May 18, 2007, the Examiner informed Applicants' attorney that he was rejoining Groups II and III (Office Action of April 6, 2007) with elected Group I. The Examiner further indicated that each of Groups I-V should indicate that  $Y^1 = Y^2 = O$  (instead of  $Y^2 = Y^2 = O$ ); that Groups II and III should indicate that  $Ar^2$  is phenyl or biphenyl; and that Group V should include all of the compounds other than those defined in Groups I-IV. The Examiner then proposed amendments to place the application in condition for allowance, and further proposed correction of spelling errors on pages 18, 19 and 21 of the specification.

After further discussions with the Examiner about the scope of allowable claims, and faxing proposals for amending the claims to the Examiner, an agreement was reached on the scope of the claims to be allowed. Referring to Proposed Claim Sets A-1, A-2, B-1 and B-2, faxed to the Examiner on May 25, 2007, it was agreed that Applicants would amend the claims as in claim set B-2 except that Z would refer to (Z-1) to (Z-3), and the word "like." (a clerical error) after claim 7 would be deleted.

#### Amendments

Claim 1 has now been amended as agreed upon. That is, claim 1 as set forth above is of the same scope as claim 1 in claim set B-2, with Z referring only to (Z-1) to (Z-3).

The spelling errors pages 18, 19 and 21 as noted by the Examiner, have been corrected as suggested by the Examiner.


Applicants emphasize that the foregoing amendments are without prejudice to their rights under 35 U.S.C. §121 to file a divisional application for the subject matter which has been deleted from the present claims.

The application is now considered to be in condition for allowance, and such allowance is solicited.

Respectfully submitted,

Shinya TANAKA et al.

By:



Michael R. Davis

Registration No. 25,134

Attorney for Applicants


MRD/pth  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
June 5, 2007

10560891

Element Count :  
Node 18: Limited  
C,C4-5  
N,N1-2

L9 STRUCTURE UPLOADED

=> d 19  
L9 HAS NO ANSWERS  
L9 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 19  
SAMPLE SEARCH INITIATED 16:24:54 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7347 TO ITERATE

27.2% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 141802 TO 152078  
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> s 19 full  
FULL SEARCH INITIATED 16:25:03 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 145946 TO ITERATE

100.0% PROCESSED 145946 ITERATIONS 13 ANSWERS  
SEARCH TIME: 00.00.01

L11 13 SEA SSS FUL L9


=> d scan

10560891


L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)  
MF (C35 H29 N O6 . C13 H14 N2)x  
CI PMS

CM 1


PAGE 1-A



PAGE 2-A



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-


10560891

(oxiranylmethoxy)phenoxy]pyridine (9CI)


MF (C29 H25 N O6 . C13 H14 N2)x

CI PMS

CM 1



CM 2



L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN



IN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy]biphenyl]-4-yl]oxy]pyridine (9CI)

MF (C39 H37 N O8 . C13 H14 N2)x


CI PMS

CM 1







CM 2





L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Pyridine, 2,6-bis[[4'-(1-(oxiran-2-ylmethoxy)ethyl]oxy]biphenyl-4-yl]oxy]-(9CI)  
 MF C39 H37 N O6  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Guanidine, cyano-, polymer with 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)  
 MF (C39 H37 N O6 . C2 H4 N4)x  
 CI PMS

CM 1




CM 2




L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Pyridazine, 3,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI)  
 MF C34 H28 N2 O6

PAGE 1-A




PAGE 1-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 13 ANSWERS . REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Pyridine, 2-[[4'-(oxiranylmethoxy) [1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI)  
 MF C29 H25 N O6  
 CI COM





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy) [1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)  
 MF (C35 H29 N O6 . C10 H10 N2)x  
 CI PMS


10560891

CM 1


PAGE 1-A





PAGE 2-A



CM 2





L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyridine, 2,6-bis[[4'-(2-(oxiran-2-ylmethoxy)ethoxy)[1,1'-biphenyl]-4-yl]oxy]-(9CI)  
MF C39 H37 N O8  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 13 ANSWERS. REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Guanidine, cyano-, polymer with 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)  
 MF (C39 H37 N O8 . C2 H4 N4)x  
 CI PMS

CM 1





CM 2



L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Methanedianine, N,N'-dimethyl-, polymer with 2,6-bis[[4'-[1-(oxiran-2-ylmethoxy)ethyl]-1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)  
 MF (C39 H37 N O6 . C3 H10 N2)x  
 CI PMS

CM 1






CM 2




L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy] - (9CI)  
 MF C35 H29 N O6  
 CI COM





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L11 13 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Pyrimidine, 4-methyl-2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy] - (9CI)  
 MF C35 H30 N2 O6





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

345.10

523.44

FILE 'CAPLUS' ENTERED AT 16:25:20 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 May 2007 VOL 146 ISS 21

FILE LAST UPDATED: 15 May 2007 (20070515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 16 MAY 2007)

FILE 'REGISTRY' ENTERED AT 15:58:01 ON 16 MAY 2007

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 2 S L1 FULL

FILE 'STNGUIDE' ENTERED AT 16:00:18 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 16:02:24 ON 16 MAY 2007

L4 STRUCTURE UPLOADED

L5 0 S L4

FILE 'STNGUIDE' ENTERED AT 16:05:42 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 16:22:53 ON 16 MAY 2007

L6 STRUCTURE UPLOADED

L7 0 S L6

L8 3 S L6 FULL

10560891

L9                   STRUCTURE UPLOADED  
L10                  0 S L9  
L11                  13 S L9 FULL

FILE 'CAPLUS' ENTERED AT 16:25:20 ON 16 MAY 2007

=> s l11

L12                  3 L11

=> d cbib abs hitstr 1-3

L12 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

2006:1030337 Document No. 145:378329 Epoxy compounds having alkylene ether chains and low melting point and their resin cured products. Hibino, Hiroaki; Inoue, Kazuya (Sumitomo Chemical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2006265110 A 20061005, 24pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2005-81361 20050322.

AB The compds. are represented by GyZAr1X1YX2Ar2ZGy [Gy = glycidyl; X1, X2 = O, single bond, CO2; Y = C1-18 linear alkylene, R1- and R2-disubstituted pyridinediyl; R1, R2 = H, C1-18 alkyl; Z = C2-18 branched linear alkylene; Ar1, Ar2 = R3R4C6H2AC6H2R5R6 [A = single bond, CR7:CH, C.tplbond.C, CH:N, OCO; R3-R7 = H, halo, C1-8 alkyl(oxy), cyano, nitro]]. Compns. of the compds. and their hardeners, their cured products, and B-staged prepreps therefrom are also claimed. Thus, 4-hydroxy-4'-acetylbiphenyl was reacted with 1,2-bis(2-chloroethoxy)ethane in the presence of NaOH to give 1,8-bis[4-(4-acetylphenyl)phenoxy]-3,6-dioxaoctane, which was reacted with NaBH4 at 50° and then with HCl to give 1,8-bis[4-[4-(1-hydroxyethyl)phenyl]phenoxy]-3,6-dioxaoctane (I). Then, I was reacted with epichlorohydrin at 50° in the presence of Bu4NBr to give 1,8-bis[4-[4-(3-oxiranyl-1-methyl-2-oxapropyl)phenyl]phenoxy]-3,6-dioxaoctane in 75% yield and purity 98%, 100 parts of which was formulated with dimethyldiaminomethane to show curing temperature 170°.



IT 910792-68-6P

RL: IMF (Industrial manufacture); RCT (Reactant); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(low-m.p. epoxy compds. having alkylene chains and good handling property for forming prepreps)

RN 910792-68-6 CAPLUS

CN Pyridine, 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]-(9CI) (CA INDEX NAME)



IT 910792-73-3P 910792-74-4P

RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(low-m.p. epoxy compds. having alkylene chains and good handling property for forming prepreps)



RN 910792-73-3 CAPLUS

CN Methanedianiline, N,N'-dimethyl-, polymer with 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 910792-68-6


CMF C39 H37 N O6



CM 2

CRN 4410-94-0

CMF C3 H10 N2





RN 910792-74-4 CAPLUS

CN Guanidine, cyano-, polymer with 2,6-bis[[4'-[1-(oxiranylmethoxy)ethyl][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 910792-68-6


CMF C39 H37 N O6



CM 2

CRN 461-58-5

CMF C2 H4 N4



L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

2006:627670 Document No. 145:84084 Epoxy compounds, compositions containing them, cured epoxy resins therefrom, and prepregs containing them. Hibino, Hiroaki; Tanaka, Shinya (Sumitomo Chemical Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2006169425 A 20060629, 17 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2004-365798 20041217.

AB The epoxy compds. GZOAr1OQOAr2OZG [G = glycidyl; Q = R1- and R2-substituted pyridinediyl; R1, R2 = H, C1-18 alkyl; Ar1, Ar2 = (un)substituted biphenylene, (un)substituted naphthalenediyl; Z = branched C2-18 alkylene, C2-18 alkylene whose  $\geq 1$  C-C single bond is

substituted by O], which can be induced to liquid-crystalline epoxy resin cured products, are prepared Thus, 630 parts 4,4'-biphenol was treated with 100 parts 2,6-dichloropyridine at 120° in DMSO in the presence of NaOH to give 159 parts 2,6-bis[4-(4-hydroxyphenyl)phenoxy]pyridine, 100 parts of which was treated with 110 parts 2-(2-chloroethoxy)tetrahydro-2H-pyran at 80° in DMSO in the presence of KOH and Bu4NBr to give 67.1 parts 2,6-bis[4-[4-(2-hydroxyethoxy)phenyl]phenoxy]pyridine (I). Then, 100 parts I was treated with 860 parts epichlorohydrin in the presence of NaOH and Et4NCl to give 110.8 parts 2,6-bis[4-[4-[2-(oxiranylmethoxy)ethoxy]phenyl]phenoxy]pyridine, 20 parts of which was mixed with 3 parts 4,4'-diaminodiphenylmethane and heated to give a liquid-crystalline cured product having good thermal conductivity

IT 893418-58-1P 893418-59-2P

RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(pyridine-based epoxy resins for liquid-crystalline cured products)

RN 893418-58-1 CAPLUS


CN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)


CM 1

CRN 893418-57-0

CMF C39 H37 N O8


PAGE 1-A





CM 2


CRN 101-77-9  
CMF C13 H14 N2




RN 893418-59-2 CAPLUS  
CN Guanidine, cyano-, polymer with 2,6-bis[[4'-[2-(oxiran-2-ylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 893418-57-0  
CMF C39 H37 N O8








CM 2

CRN 461-58-5

CMF C2 H4 N4




IT 893418-57-0P


RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(pyridine-based epoxy resins for liquid-crystalline cured products)

RN 893418-57-0 CAPLUS

CN Pyridine, 2,6-bis[[4'-[2-(oxiranylmethoxy)ethoxy][1,1'-biphenyl]-4-yl]oxy]-(9CI) (CA INDEX NAME)





L12 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

2004:1154700 Document No. 142:75325 Epoxy compound and amine-cured epoxy resin product. Tanaka, Shinya; Takezawa, Yoshitaka; Takahashi, Hiroyuki (Sumitomo Chemical Company, Limited, Japan; Hitachi, Ltd.). PCT Int.

Appl. WO 2004113327 A1 20041229, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-JP8934 20040618.

PRIORITY: JP 2003-174545 20030619.

AB The epoxy compound, which can be converted into a cured epoxy resin product having liquid crystal properties is obtained by curing with amine (or phenol) curing agent. Since the cured epoxy resin product exhibits good heat conductivity, it is also useful as an insulating material requiring high heat releasability such as a printed circuit substrate and the like. An example resin precursor 2,6-bis[4-[4-(oxiranylmethoxy)phenyl]phenoxy]pyridine had m.p. 157-160°.




IT 815600-49-8P 815600-51-2P 815600-53-4P  
815600-56-7P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)



(preparation and curing; pyridine condensate epoxy compound and cured epoxy resin product)

RN 815600-49-8 CAPLUS

CN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy] - (9CI)  
(CA INDEX NAME)



RN 815600-51-2 CAPLUS  
 CN Pyridazine, 3,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy] - (9CI)  
 (CA INDEX NAME)




10560891

RN 815600-53-4 CAPLUS

CN Pyrimidine, 4-methyl-2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 815600-56-7 CAPLUS

CN Pyridine, 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



IT 815600-57-8P 815600-58-9P 815600-59-0P

RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)  
(pyridine condensate epoxy compound and cured epoxy resin product)



RN 815600-57-8 CAPLUS

CN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1


CRN 815600-49-8

CMF C35 H29 N O6



CM 2



CRN 101-77-9  
 CMF C13 H14 N2



RN 815600-58-9 CAPLUS  
 CN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1


CRN 815600-49-8  
 CMF C35 H29 N O6



CM 2

CRN 2243-62-1

CMF C10 H10 N2




RN 815600-59-0 CAPLUS


CN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy) [1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 815600-56-7  
CMF C29 H25 N O6



CRN 101-77-9  
CMF C13 H14 N2



CA SUBSCRIBER PRICE

SINCE FILE ENTRY	TOTAL SESSION
-2.34	-2.34

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: May 11, 2007 (20070511/UP).

 $\Rightarrow$

10560891

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptadko1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/Caplus updated with revised CAS roles
NEWS	7	JAN 22	CA/Caplus enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	26	APR 30	CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS	27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	28	MAY 01	New CAS web site launched
NEWS	29	MAY 08	CA/Caplus Indian patent publication number format defined
NEWS	30	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS EXPRESS		NOVEMBER 10	CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation



10560891

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:32:41 ON 16 MAY 2007

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:33:10 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10560891\_resin.str



chain nodes :

1 9

ring/chain nodes :

2 3 5 6 11 12

chain bonds :

1-2 1-3 5-9 9-11

10560891

2. An Ak node attached to another Ak node.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.70

2.91

FILE 'STNGUIDE' ENTERED AT 14:36:46 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 11, 2007 (20070511/UP).

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

2.97

FILE 'REGISTRY' ENTERED AT 14:37:38 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\1560891resin.str

10560891



chain nodes :

1 9

ring/chain nodes :

2 3 5 6 11 12

chain bonds :

1-2 1-3 5-9 9-11

ring/chain bonds :

2-5 3-6 11-12

exact/norm bonds :

1-2 1-3 2-5 3-6 11-12

exact bonds :

5-9 9-11

Match level :

1:Atom 2:CLASS 3:CLASS 5:Atom 6:Atom 9:Atom 11:CLASS 12:CLASS

Generic attributes :

5:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

6:

Saturation : Unsaturated

Type of Ring System : Monocyclic

9:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 1: Limited

C,C4-5

N,N1-2

Node 5: Limited

C,C6

Node 6: Limited

C,C6

Node 9: Limited

C,C6


L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS

L2 STR

10560891



Structure attributes must be viewed using STN Express query preparation.

=> s 12

GENERIC GROUP NOT VALID HERE

Generic groups may not be used in these circumstances:

1. Any generic group node (e.g., Hy) in a ring.
2. An Ak node attached to another Ak node.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.45

3.42

FILE 'STNGUIDE' ENTERED AT 14:38:22 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 11, 2007 (20070511/UP).

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.54

3.96

FILE 'REGISTRY' ENTERED AT 14:44:02 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

10560891

Uploading C:\Program Files\Stnexp\Queries\10560891blah.str



chain nodes :  
1 2 3 4 5 6 7  
ring nodes :  
12 13 14  
chain bonds :  
1-2 1-3 2-4 3-5 4-6 6-7  
ring bonds :  
12-13 12-14 13-14  
exact/norm bonds :  
1-2 1-3 12-13 12-14 13-14  
exact bonds :  
2-4 3-5 4-6 6-7

Match level :  
1:Atom 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:CLASS 12:Atom 13:Atom  
14:Atom

Generic attributes :

1:  
Saturation : Unsaturated  
4:  
Saturation : Unsaturated  
5:  
Saturation : Unsaturated  
6:  
Saturation : Unsaturated

Element Count :  
Node 1: Limited  
C,C4-5  
N,N1-2

Node 4: Limited  
C,C3

Node 5: Limited  
C,C6

Node 6: Limited  
C,C6


L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR

10560891



Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 14:44:19 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 174377 TO ITERATE

1.1% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 3462969 TO 3512111  
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s l3 full

FULL SEARCH INITIATED 14:44:46 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 3496598 TO ITERATE

28.4% PROCESSED 993395 ITERATIONS 0 ANSWERS  
28.6% PROCESSED 1000000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.17

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 3496598 TO 3496598  
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS FUL L3

=> FIL STNGUIDE  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
172.55	176.51

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 14:45:20 ON 16 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: May 11, 2007 (20070511/UP).

10560891

=> FIL REGISTRY  
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.36	176.87

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:49:07 ON 16 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2  
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10560891resinc.str



chain nodes :

7 9 10 13 14

ring nodes :

1 2 3 4 5 6 15 16 17

chain bonds :

7-9 9-10 10-13 13-14 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-17 16-17

exact/norm bonds :

13-14 15-16 15-17 16-17

exact bonds :

7-9 9-10 10-13 14-15

normalized bonds :

10560891

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom

Generic attributes :

9:

Saturation : Unsaturated

10:

Saturation : Unsaturated

Element Count :

Node 9: Limited  
C,C6


Node 10: Limited  
C,C6

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 16

SAMPLE SEARCH INITIATED 14:49:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1263 TO ITERATE

100.0% PROCESSED 1263 ITERATIONS  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*



10560891

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 23128 TO 27392  
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s l7 full

FULL SEARCH INITIATED 14:49:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 24932 TO ITERATE

100.0% PROCESSED 24932 ITERATIONS  
SEARCH TIME: 00.00.02

5 ANSWERS

L8 5 SEA SSS FUL L6

=> d scan

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN


IN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-(oxiranylethoxy)]-1,1'-biphenyl]-4-ylloxy]pyridine (9CI)

MF (C35 H29 N O6 . C13 H14 N2)x


CI PMS

CM 1

PAGE 1-A




PAGE 2-A



10560891


CM 2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]pyridine (9CI)  
MF (C29 H25 N O6 . C13 H14 N2)x  
CI PMS

CM 1




CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyridine, 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI)  
MF C29 H25 N O6  
CI COM

10560891






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranymethoxy)[1,1'-  
biphenyl]-4-yl]oxy]pyridine (9CI)  
MF (C35 H29 N O6 . C10 H10 N2)x  
CI PMS

CM 1






CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy] - (9CI)  
 MF C35 H29 N O6  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> 1

1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

349.42

FILE 'CAPLUS' ENTERED AT 14:50:31 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

10560891

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 May 2007 VOL 146 ISS 21  
FILE LAST UPDATED: 15 May 2007 (20070515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 14:32:41 ON 16 MAY 2007)

L1 FILE 'REGISTRY' ENTERED AT 14:33:10 ON 16 MAY 2007  
STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:36:46 ON 16 MAY 2007

L2 FILE 'REGISTRY' ENTERED AT 14:37:38 ON 16 MAY 2007  
STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:38:22 ON 16 MAY 2007

L3 FILE 'REGISTRY' ENTERED AT 14:44:02 ON 16 MAY 2007  
STRUCTURE UPLOADED

L4 0 S L3

L5 0 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 14:45:20 ON 16 MAY 2007

L6 FILE 'REGISTRY' ENTERED AT 14:49:07 ON 16 MAY 2007  
STRUCTURE UPLOADED

L7 0 S L6

L8 5 S L7 FULL

FILE 'CAPLUS' ENTERED AT 14:50:31 ON 16 MAY 2007

=> s l8

L9 1 L8

=> d cbib abs hitstr

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
2004:1154700 Document No. 142:75325 Epoxy compound and amine-cured epoxy resin product. Tanaka, Shinya; Takezawa, Yoshitaka; Takahashi, Hiroyuki (Sumitomo Chemical Company, Limited, Japan; Hitachi, Ltd.). PCT Int. Appl. WO 2004/113327 A1 20041229, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.

10560891

(English). CODEN: PIXXD2. APPLICATION: WO 2004-JP8934 20040618.  
PRIORITY: JP 2003-174545 20030619.

AB The epoxy compound, which can be converted into a cured epoxy resin product having liquid crystal properties is obtained by curing with amine (or phenol) curing agent. Since the cured epoxy resin product exhibits good heat conductivity, it is also useful as an insulating material requiring high heat releasability such as a printed circuit substrate and the like. An example resin precursor 2,6-bis[4-[4-(oxiranylmethoxy)phenyl]phenoxy]pyridine had m.p. 157-160°.

IT 815600-49-8P 815600-56-7P


RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(preparation and curing; pyridine condensate epoxy compound and cured epoxy resin product)


RN 815600-49-8 CAPLUS

CN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI)  
(CA INDEX NAME)

PAGE 1-A



10560891



IT 815600-57-8P 815600-58-9P 815600-59-0P

RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)  
(pyridine condensate epoxy compound and cured epoxy resin product)

RN 815600-57-8 CAPLUS


CN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-(oxiranymethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1


CRN 815600-49-8

CMF C35 H29 N O6

PAGE 1-A








CM 2



CRN 101-77-9  
 CMF C13 H14 N2




RN 815600-58-9 CAPLUS  
 CN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 815600-49-8  
 CMF C35 H29 N O6






CM 2

CRN 2243-62-1

CMF C10 H10 N2




RN 815600-59-0 CAPLUS

CN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]pyridine (9CI) (CA INDEX NAME)

CM 1

CRN 815600-56-7

CMF C29 H25 N O6




CM 2

CRN 101-77-9

CMF C13 H14 N2

10560891



=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.15	356.57

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.78	-0.78

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 14:52:57 ON 16 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 11, 2007 (20070511/UP).

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.42	356.99

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.78

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 14:57:15 ON 16 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2  
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10560891alcohol.str

10560891



chain nodes :

7 9 10 13 14

ring nodes :

1 2 3 4 5 6

chain bonds :

7-9 9-10 10-13 13-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact bonds :

7-9 9-10 10-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

13:CLASS 14:CLASS

Generic attributes :

9:

Saturation : Unsaturated

10:

Saturation : Unsaturated

Element Count :

Node 9: Limited

C,C6

Node 10: Limited


C,C6

L10 STRUCTURE UPLOADED

=> d l10

L10 HAS NO ANSWERS

L10 STR



Structure attributes must be viewed using STN Express query preparation.

10560891

=> s l10

SAMPLE SEARCH INITIATED 14:57:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 165362 TO ITERATE

1.2% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 3283288 TO 3331192  
PROJECTED ANSWERS: 0 TO 0

L11 0 SEA SSS SAM L10

=> s l10 full

FULL SEARCH INITIATED 14:57:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3308614 TO ITERATE

29.9% PROCESSED 989187 ITERATIONS ( 1 INCOMPLETE)

4 ANSWERS

30.2% PROCESSED 1000000 ITERATIONS ( 1 INCOMPLETE)

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.17

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 3308614 TO 3308614  
PROJECTED ANSWERS: 4 TO 23

L12 4 SEA SSS FUL L10

=> dscan

DSCAN IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).


=> d scan

L12 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN [1,1'-Biphenyl]-4-ol, 3-methoxy-4'-[[2-(1H-tetrazol-5-yl)thieno[2,3-  
c]pyridin-4-yl]oxy]- (9CI)

MF C21 H15 N5 O3 S

10560891



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
ITERATION INCOMPLETE

IN Poly[spiro[2H-isoindolium-2,7'-[1,4,10,13]tetraoxa[16]aza[7]azoniacyclooct  
adecane]-16',16':5,6-tetrayl-5,6-bis(methylene)] (9CI)

MF (C22 H34 N2 O4)n

CI PMS, COM




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L12 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN [1,1'-Biphenyl]-4-ol, 4'--[(6-chloro-2-pyridinyl)oxy] - (9CI)

MF C17 H12 Cl N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10560891

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

174.35

531.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-0.78

FILE 'CAPLUS' ENTERED AT 15:00:41 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 May 2007 VOL 146 ISS 21

FILE LAST UPDATED: 15 May 2007 (20070515/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 14:32:41 ON 16 MAY 2007)

FILE 'REGISTRY' ENTERED AT 14:33:10 ON 16 MAY 2007

L1 STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:36:46 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:37:38 ON 16 MAY 2007

L2 STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:38:22 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:44:02 ON 16 MAY 2007

L3 STRUCTURE UPLOADED

L4 0 S L3

L5 0 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 14:45:20 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:49:07 ON 16 MAY 2007

L6 STRUCTURE UPLOADED

L7 0 S L6

L8 5 S L7 FULL

FILE 'CAPLUS' ENTERED AT 14:50:31 ON 16 MAY 2007

L9 1 S L8

10560891

FILE 'STNGUIDE' ENTERED AT 14:52:57 ON 16 MAY 2007

FILE 'REGISTRY' ENTERED AT 14:57:15 ON 16 MAY 2007

L10 STRUCTURE UPLOADED

L11 0 S L10

L12 4 S L10 FULL

FILE 'CAPLUS' ENTERED AT 15:00:41 ON 16 MAY 2007

=> s l12

L13 2 L12

=> d scan

L13 2 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN

IC ICM C07D405-14

CC 37-3 (Plastics Manufacture and Processing)

Section cross-reference(s): 38, 76

TI Epoxy compound and amine-cured epoxy resin product

ST epoxy resin liq cryst cured insulator circuit board; biphenylene  
pyridindiyldiglycidyl ether

IT Reinforced plastics

RL: TEM (Technical or engineered material use); USES (Uses)  
(prepregs; pyridine condensate epoxy compound and cured epoxy resin  
product for)

IT Epoxy resins, preparation

RL: IMF (Industrial manufacture); PREP (Preparation)  
(pyridine condensate epoxy compound and cured epoxy resin product)

IT Electric insulators

Printed circuit boards

(pyridine condensate epoxy compound and cured epoxy resin product for)

IT 815600-49-8P 815600-51-2P 815600-53-4P 815600-56-7P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and curing; pyridine condensate epoxy compound and cured epoxy  
resin product)

IT 815600-61-4P

RL: IMF (Industrial manufacture); PREP (Preparation)  
(pyridine condensate epoxy compound and cured epoxy resin product)

IT 815600-57-8P 815600-58-9P 815600-59-0P

RL: IMF (Industrial manufacture); PRP (Properties); PREP (Preparation)  
(pyridine condensate epoxy compound and cured epoxy resin product)

IT 815600-54-5P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT  
(Reactant or reagent)  
(pyridine condensate epoxy compound and cured epoxy resin product)

IT 92-88-6, 4,4'-Biphenol 106-89-8, Epichlorohydrin, reactions 141-30-0,  
3,6-Dichloropyridazine 626-16-4, 1,3-Bis(chloromethyl)benzene  
2402-78-0, 2,6-Dichloropyridine 5424-21-5, 2,4-Dichloro-6-  
methylpyrimidine

RL: RCT (Reactant); RACT (Reactant or reagent)  
(pyridine condensate epoxy compound and cured epoxy resin product)

IT 30062-98-7P 815600-50-1P 815600-52-3P 815600-55-6P

815600-60-3P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT  
(Reactant or reagent)  
(reaction with epichlorohydrin; pyridine condensate epoxy compound and  
cured epoxy resin product)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L13 2 ANSWERS CAPLUS COPYRIGHT 2007 ACS on STN

IC ICM A61K031-4743



ICS C07D498-02

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

TI Preparation of fused heterocycle kinase inhibitors for treatment of protein tyrosine kinase-related diseases

ST fused heterocycle prepn kinase inhibitor collagen induced arthritis; thienopyridine furopyridine pyrrolopyridine naphthyridine prepn COT MK2 kinase inhibitor; TNFa interleukin1 prodn inhibitor thienopyridine prepn

IT Growth factor receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(angiogenic factor; preparation of fused heterocycles as inhibitors of angiogenic receptor tyrosine kinases)

IT Growth inhibitors, animal  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(angiogenic growth-inhibiting factor; preparation of fused heterocycles as inhibitors of angiogenic receptor tyrosine kinases)

IT Angiogenesis  
(neovascularization; preparation of fused heterocycles as inhibitors of angiogenic receptor tyrosine kinases)

IT Interleukin 1  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of fused heterocycles as inhibitors of IL-1 production resulting from LPS stimulation)

IT Interleukin 1β  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of fused heterocycles as inhibitors of IL-1β production resulting from LPS stimulation)

IT Tumor necrosis factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of fused heterocycles as inhibitors of TNF-α production resulting from LPS stimulation)

IT Arthritis  
(preparation of fused heterocycles as inhibitors of collagen induced arthritis)

IT Cytokines  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of fused heterocycles as inhibitors of cytokines production resulting from LPS stimulation)

IT Lipopolysaccharides  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation of fused heterocycles as inhibitors of pErk signaling resulting from LPS stimulation)

IT Human  
(preparation of fused heterocycles as kinase inhibitors)

IT 98546-51-1P, 4-(Methylsulfanyl)phenylboronic acid 145325-40-2P, 4-Bromothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 251992-93-5P, 4-Phenylsulfanylthieno[2,3-c]pyridine-2-carboxamide 251993-33-6P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carboxamide 251993-41-6P, 4-Bromothieno[2,3-c]pyridine-2-carboxamide 251995-92-3P, 4-(3-Aminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870234-99-4P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid 870235-00-0P, 4-Bromothieno[2,3-c]pyridine-2-carbonitrile 870235-01-1P, 4-Bromo-2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridine 870235-02-2P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870235-12-4P, 4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenylamine 870235-15-7P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic acid 870235-18-0P, 4-[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]piperazine-1-carboxylic acid tert-butyl ester 870235-19-1P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870235-20-4P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid ditrifluoroacetate 870235-24-8P, 4-(Biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-28-2P, 4-(3-Formylphenyl)thieno[2,3-

c]pyridine-2-carboxamide 870235-32-8P, 4-Bromo-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-34-0P, 4-[(Biphenyl-4-yl)amino]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-41-9P  
 870235-43-1P, 4-[4-(2-Chloroacetyl amino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-44-2P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870235-45-3P, 4-Fluorothieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870235-48-6P, 4-[(Biphenyl-4-yl)amino]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870235-49-7P,  
 4-[(Biphenyl-4-yl)oxy]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-51-1P, 4-(3-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-52-2P 870235-55-5P, 4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870235-76-0P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carbonitrile 870235-77-1P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carbonitrile 870235-78-2P, 4-[(Biphenyl-4-yl)amino]-7-chlorothieno[2,3-c]pyridine-2-carboxamide 870235-80-6P,  
 4-[3-[3-(m-Tolyl)ureido]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-82-8P, 4-(Biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870235-83-9P, 4-(Biphenyl-3-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-18-3P, 4-(1H-Pyrazol-4-yl)thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-27-4P, 4-[(Biphenyl-4-yl)amino]-7-cyanothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870236-42-3P,  
 4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester 870236-44-5P, (R)-3-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]pyrrolidine-1-carboxylic acid tert-butyl ester 870237-40-4P, 4-(4-Aminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-79-9P, [3-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-30-5P, 4-[(4'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic acid 870238-31-6P, 4-(Biphenyl-3-yl)pyrrolo[2,3-c]pyridine-2-carboxylic acid 870238-39-4P, 4-Bromo-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870238-48-5P,  
 7-Amino-4-bromothieno[2,3-c]pyridine-2-carboxamide 870238-49-6P, 7-Amino-4-(3-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-64-5P, 4'-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]biphenyl-4-carboxylic acid 870238-82-7P, 4-[(Piperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870240-02-1P, [4-[(4'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]carbamic acid tert-butyl ester 870240-10-1P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid (2-tert-butoxyethoxy)amide 870240-11-2P, 4-[[4-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)phenyl]carbamoyl]piperidine-1-carboxylic acid tert-butyl ester 870240-40-7P, 3-[[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]propionic acid tert-butyl ester 870241-11-5P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine 870241-33-1P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxaldehyde 870241-34-2P, (1S,4S)-4-(2,5-Diazabicyclo[2.2.1]hept-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870241-35-3P,  
 4-((1S,4S)-5-Benzyl-2,5-diazabicyclo[2.2.1]hept-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870241-36-4P, 4-((3R)-Pyrrolidin-3-ylamino)thieno[2,3-c]pyridine-2-carboxamide 870241-37-5P, 4-[(R)-1-Benzylpyrrolidin-3-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-71-7P,  
 4-(Biphenyl-3-yl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester 870241-74-0P, 4-(Biphenyl-3-yl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 870242-92-5P, 4-Bromopyrrolo[2,3-c]pyridine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 870242-94-7P, [7-(Biphenyl-3-yl)-3-bromothieno[2,3-c]pyridin-4-yl]amine 870242-95-8P, [7-(Biphenyl-3-yl)-3-cyanothieno[2,3-c]pyridin-4-yl]amine 870243-07-5P, 4-Chlorofuro[2,3-c]pyridine-2-carboxylic acid ethyl ester 870243-08-6P 870243-10-0P, N-Hydroxy-4-(4-iodophenoxy)thieno[2,3-c]pyridine-2-carboximidamide 870243-13-3P, 4-[(Biphenyl-4-yl)oxy]-N-hydroxythieno[2,3-c]pyridine-2-carboximidamide 870243-27-9P, 4-Bromo-6-oxothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-29-1P, 4-[(Biphenyl-4-yl)amino]-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-31-5P,  
 7-Amino-4-[(biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-37-1P, [[4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-

2-yl)methyl]amine 870243-51-9P, 7-(Biphenyl-3-yl)thieno[2,3-c]pyridin-4-amine 870243-64-4P, (2-Methoxycarbonylthieno[2,3-c]pyridin-4-yl)ammonium chloride 870243-70-2P, [2-(5-Amino-[1,2,4]oxadiazol-3-yl)thieno[2,3-c]pyridin-4-yl](biphenyl-4-yl)amine 870243-75-7P 870243-84-8P, 3-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-3-oxopropionitrile 870243-89-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic hydrazide 870244-11-4P, N'-(Biphenyl-4-yl)thieno[2,3-c]pyridine-2,4-diamine dihydrochloride 870244-24-9P, 4-(Biphenyl-3-yl)-5-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-27-2P, 5-Chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-28-3P, 4-Bromo-3-methylthieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-30-7P, 4-(4-Bromophenylamino)-3-methylthieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-37-4P, 4-(Biphenyl-3-yl)-1-(2-methoxycarbonylethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid methyl ester

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 2646-90-4P, 2,5-Difluorobenzaldehyde 5470-96-2P, 2-Quinolincarboxaldehyde 5779-95-3P, 3,5-Dimethylbenzaldehyde 5973-71-7P, 3,4-Dimethylbenzaldehyde 10203-08-4P, 3,5-Dichlorobenzaldehyde 22078-59-7P, 5-(3-Chlorophenyl)furan-2-carboxaldehyde 63019-98-7P, (3-Methylbiphenyl-4-yl)amine 251993-28-9P, 4-Phenoxythieno[2,3-c]pyridine-2-carboxamide 251993-43-8P, 4-(4-Trifluoromethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 251993-45-0P, 4-Phenylthieno[2,3-c]pyridine-2-carboxamide 251995-86-5P, 251995-88-7P, 4-(4-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 251995-89-8P, 4-(3-Trifluoromethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 251995-94-5P, 4-(3,5-Dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 251996-53-9P 870235-03-3P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870235-05-5P, (5-Phenylpyridin-2-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-06-6P 870235-07-7P, 4-(Phenethynyl)thieno[2,3-c]pyridine-2-carboxamide 870235-08-8P, 4-[4-[(Phenylsulfonyl)amino]phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870235-09-9P, 4-[3-[(Cyclopropylmethyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-10-2P, 4-[4-(3-Phenylureido)phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870235-11-3P, N-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-trifluoromethylbenzamide 870235-13-5P, [3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)phenyl]carbamic acid isopropyl ester 870235-16-8P, [4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]amine 870235-17-9P, 4-[3-[[[Pyridin-4-yl]carbonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-21-5P, 4-[(2,6-Dimethylbiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870235-22-6P, 4-(3-Isopropoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870235-25-9P, 4-[(Biphenyl-4-yl)oxy]-2-phenylthieno[2,3-c]pyridine 870235-27-1P, 4-[3-[[[2-(Piperidin-1-yl)ethyl]amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-29-3P, 4-[[4-(Thiophen-3-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870235-33-9P, 4-[(Biphenyl-4-yl)amino]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 870235-38-4P, [4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]acetic acid 870235-40-8P, 1-[4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]pyrrolidine-2,5-dione 870235-42-0P, 4-[4-[[2-(Pyrazol-1-yl)acetyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870235-46-4P, 4-Fluorothieno[2,3-c]pyridine-2-carboxylic acid 870235-50-0P, 4-[(Biphenyl-4-yl)oxy]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870235-53-3P, 7-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870235-57-7P, 3'-(7-Amino-2-carbamoylthieno[2,3-c]pyridin-4-yl)biphenyl-4-carboxylic acid 870235-59-9P, 7-Amino-4-(3',4'-dimethoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-61-3P, 7-Amino-4-(4'-carbamoylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-

carboxylic acid 870235-63-5P, 7-Amino-4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-65-7P, 7-Amino-4-[3-(benzo[b]thiophen-3-yl)phenyl]thieno[2,3-c]pyridine-2-carboxylic acid 870235-67-9P, 7-Amino-4-(4'-ethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-69-1P, 7-Amino-4-[3-(pyridin-4-yl)phenyl]thieno[2,3-c]pyridine-2-carboxylic acid 870235-71-5P, 7-Amino-4-(3'-methylsulfonylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-73-7P, 4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870235-75-9P, 5-[(Biphenyl-3-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870235-79-3P, 4-[(Biphenyl-4-yl)amino]-7-chlorothieno[2,3-c]pyridine-2-carbonitrile 870235-81-7P, 1-[3-(2-Cyanothieno[2,3-c]pyridin-4-yl)phenyl]-3-(m-tolyl)urea 870235-85-1P, (3,5-Dimethylbiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-87-3P, (3-Fluorobiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-89-5P, (3-Chlorobiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-91-9P, [2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl](3-trifluoromethylbiphenyl-4-yl)amine 870235-93-1P, [2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl](2-trifluoromethylbiphenyl-4-yl)amine 870235-95-3P, (3-Methylbiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-96-4P, 4-(Biphenyl-3-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870235-98-6P, 4-[(2-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-00-3P, 4-[(3,5-Difluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-01-4P, 4-[(3,5-Difluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-02-5P, 4-[(3,5-Dimethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-03-6P, 4-[(3-Fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-04-7P, 4-[(3-Fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-05-8P, 4-[(3-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-06-9P, 4-[(3-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-07-0P, 4-[(3-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-08-1P, 4-[(2-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-09-2P, 4-[(2-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-10-5P, 4-[(3-Methoxybiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-12-7P, 4-[(3-Methoxybiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-14-9P, 4-(3-Chlorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870236-15-0P, 4-[(2-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-16-1P, 4-[(3-Methylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-17-2P, 4-[(3-Methylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-19-4P, 4-(1H-Pyrazol-4-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870236-21-8P, 4-(4-Hydroxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-23-0P, 4-(4-Aminophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-25-2P, 4-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)benzoic acid 870236-26-3P, 4-(4-Hydroxyphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870236-28-5P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2,7-dicarboxylic acid 870236-29-6P, 4-(4-Aminophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870236-31-0P, 4-(Cyclohexylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-33-2P, 4-(4-Phenylcyclohexylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-35-4P, 4-[(1-Benzylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-36-5P, 4-[(1-Benzylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-38-7P, (1R,5R)-6-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylic acid benzyl ester 870236-40-1P, 4-[(4'-Formylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-46-7P, 4-((3AS,6aR)-5-Benzylhexahydropyrrolo[3,4-c]pyrrol-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870236-48-9P, 4-(2-Benzyloctahydropyrrolo[3,4-c]pyridin-5-yl)thieno[2,3-c]pyridine-2-

carboxamide 870236-50-3P, 4-(2-Benzyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)thieno[2,3-c]pyridine-2-carboxamide 870236-52-5P, 4-(1-Oxo-2-phenyl-2,8-diazaspiro[4.5]decan-8-yl)thieno[2,3-c]pyridine-2-carboxamide 870236-54-7P, (1R,4S)-5-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 870236-55-8P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-56-9P, 4-(3-Phenoxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-57-0P, 4-(4-Phenoxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-58-1P, 4-[(Naphthalen-2-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-60-5P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-61-6P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-62-7P, 4-[(Naphthalen-2-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-63-8P, 4-[[4-(Pyridin-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-64-9P, 4-[(4'-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-65-0P, 4-[(4'-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-66-1P, 4-[[4-(1H-Pyrazol-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-67-2P, 4-[(Phenyl)[2-(pyrrolidin-1-yl)ethyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-68-3P, 4-Phenylaminothieno[2,3-c]pyridine-2-carboxamide 870236-69-4P, (2-Methylbiphenyl-4-yl)[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870236-70-7P, 4-(2-Methylbiphenyl-4-ylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-72-9P 870236-74-1P, 4-[(2-Methyl-5-phenyl-2H-pyrazol-3-yl)amino]thieno[2,3-c]pyridine-2-carboxamide acetate 870236-75-2P, (4-tert-Butylphenyl)[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]amine 870236-76-3P, 4-[[4-(1H-Benzimidazol-2-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870236-77-4P, 4-[(4'-Cyanobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-78-5P, N-(2-Aminocarbonylthieno[2,3-c]pyridin-4-yl)-4-[[4-(morpholin-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870236-79-6P, 4-[[4-(Morpholin-4-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870236-80-9P, N-(2-Aminocarbonylthieno[2,3-c]pyridin-4-yl)-4-[[4-(cyclohexyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870236-81-0P, 4-(4-Cyclohexylphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-82-1P, 4-[(5-Phenylpyridin-2-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-83-2P, 4-[[4'-[2-(Piperidin-4-yl)ethyl]carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870236-84-3P, 4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-85-4P, 8-[(Biphenyl-4-yl)amino][1,6]naphthyridine-2-carboxylic acid 870236-86-5P, 4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870236-87-6P, 4-(4-Nitrophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-88-7P, 4-(3,4-Dichlorophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-89-8P, 4-[(4-Nitro-3-trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-90-1P, 4-[(2,3-Dihydrobenzo[1,4]dioxin-6-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-91-2P, 4-[(4-Trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-92-3P, 4-[(4-Fluorophenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-93-4P, 4-[(4-Chlorophenyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-94-5P, 4-(4-Ethoxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-95-6P, 4-(p-Tolylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-96-7P, 4-[(Indan-5-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870236-97-8P, 4-(4-Ethylphenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-98-9P, 4-(4-Bromo-2-fluorophenylamino)thieno[2,3-c]pyridine-2-carboxamide 870236-99-0P, 4-(3,4-Dichlorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-00-6P, 4-[(4-Nitro-3-trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-01-7P, 4-[(4-Trifluoromethylphenyl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-02-8P, 4-(4-Cyanophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-03-9P, 4-(4-Fluorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-04-0P,

4-(4-Chlorophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid  
 870237-05-1P, 4-[(4-Dimethylaminophenyl)amino]thieno[2,3-c]pyridine-2-  
 carboxylic acid 870237-06-2P, 4-(4-Methoxyphenylamino)thieno[2,3-  
 c]pyridine-2-carboxylic acid 870237-07-3P, 4-(4-  
 Ethoxyphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-08-4P,  
 4-(p-Tolylamino)thieno[2,3-c]pyridine-2-carboxylic acid 870237-09-5P,  
 4-[(Indan-5-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid  
 870237-10-8P, 4-(4-Ethylphenylamino)thieno[2,3-c]pyridine-2-carboxylic  
 acid 870237-11-9P, 4-(4-Bromo-2-fluorophenylamino)thieno[2,3-c]pyridine-  
 2-carboxylic acid 870237-12-0P, 4-[(2-Methyl-1H-indol-5-  
 yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-13-1P,  
 4-[(1H-Indol-5-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid  
 870237-14-2P, 4-[(Benzodioxol-5-yl)amino]thieno[2,3-c]pyridine-2-  
 carboxylic acid 870237-15-3P, 4-[[4-(Morpholin-4-  
 yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid 870237-16-4P,  
 4-(Acetylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid  
 870237-17-5P, 4-[(4-Trifluoromethoxyphenyl)amino]thieno[2,3-c]pyridine-2-  
 carboxamide 870237-18-6P, 4-[(2-Methylbenzothiazol-5-yl)amino]thieno[2,3-  
 c]pyridine-2-carboxamide 870237-19-7P, 4-[[3-[(Dimethylamino)methyl]-4-  
 hydroxyphenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870237-20-0P,  
 4-(4-Bromo-3-fluorophenylamino)thieno[2,3-c]pyridine-2-carboxamide  
 870237-21-1P, 4-[(1-Acetyl-2,3-dihydro-1H-indol-6-yl)amino]thieno[2,3-  
 c]pyridine-2-carboxamide 870237-22-2P, 4-(4-Vinylphenylamino)thieno[2,3-  
 c]pyridine-2-carboxamide 870237-23-3P, 4-[4-  
 (Cyanomethyl)phenylamino]thieno[2,3-c]pyridine-2-carboxamide  
 870237-24-4P, 4-(4-Propoxyphenylamino)thieno[2,3-c]pyridine-2-carboxamide  
 870237-25-5P, 4-[(4-Phenylcarbamoylphenyl)amino]thieno[2,3-c]pyridine-2-  
 carboxamide 870237-26-6P, 4-[[4-(Difluoromethoxy)phenyl]amino]thieno[2,3-  
 c]pyridine-2-carboxamide 870237-27-7P, 4-[(2-Carbamoylthieno[2,3-  
 c]pyridin-4-yl)amino]benzoic acid ethyl ester 870237-28-8P,  
 4-[[4-(Piperidin-1-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide  
 870237-29-9P, 4-[(4-Chloro-3-trifluoromethylphenyl)amino]thieno[2,3-  
 c]pyridine-2-carboxamide 870237-30-2P, 4-[[4-  
 [Cyano(phenyl)methyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide  
 870237-31-3P, 4-[(3'-Cyanobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-  
 carboxamide 870237-32-4P, 4-(5-Benzylhexahydropyrrolo[3,4-c]pyrrol-2-  
 yl)thieno[2,3-c]pyridine-2-carboxamide 870237-34-6P,  
 4-((3aS,7aR)-2-Benzyloctahydropyrrolo[3,4-c]pyridin-5-yl)thieno[2,3-  
 c]pyridine-2-carboxamide 870237-36-8P, 4-[(8-Benzyl-8-  
 azabicyclo[3.2.1]oct-3-yl)amino]thieno[2,3-c]pyridine-2-carboxamide  
 870237-37-9P, 4-[(1-Phenylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-  
 carboxamide 870237-38-0P, 4-(Naphthalen-1-yl)-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870237-39-1P, 4-([2,2']Bithiophenyl-5-yl)-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870237-41-5P, 4-(Pyridin-4-  
 yl)thieno[2,3-c]pyridine-2-carboxamide 870237-42-6P,  
 4-(2-Methylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-43-7P,  
 4-(4-Methylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-44-8P,  
 4-(4-Hydroxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-45-9P,  
 4-(3-Hydroxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-46-0P,  
 4-(2,5-Dimethylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-47-1P,  
 4-(4-Hydroxymethylphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-48-2P, 4-(3-Hydroxymethylphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-49-3P, 4-(4-Methoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-50-6P, 4-(2-Hydroxymethylphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-51-7P, 4-(5-Fluoro-2-methoxyphenyl)thieno[2,3-c]pyridine-2-  
 carboxamide 870237-52-8P, 4-(2-Fluoro-3-methoxyphenyl)thieno[2,3-  
 c]pyridine-2-carboxamide 870237-53-9P, 4-(Naphthalen-1-yl)thieno[2,3-  
 c]pyridine-2-carboxamide 870237-54-0P, 4-(Benzo[b]thiophen-2-  
 yl)thieno[2,3-c]pyridine-2-carboxamide 870237-55-1P,  
 4-(3,4-Dimethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870237-56-2P  
 870237-57-3P, 4-(Biphenyl-2-yl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-58-4P, 4-(2-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-59-5P, 4-(2,3-Difluorophenyl)thieno[2,3-c]pyridine-2-carboxamide

870237-60-8P, 4-(Benzofuran-2-yl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-61-9P, 4-(4-Acetylphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-62-0P, 4-(2,3-Dihydrobenzofuran-5-yl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-63-1P, 4-(3-Isopropylphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-64-2P, 4-(4-Dimethylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-65-3P, 4-(Benzodioxol-5-yl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-66-4P, 4-(3-Ethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-67-5P, 4-(3-Nitrophenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-68-6P, 4-(4-Methylsulfonylphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-69-7P, 4-(3-Trifluoromethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-70-0P, 4-(4-Trifluoromethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-71-1P, 4-(2-Trifluoromethoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-72-2P, 4-(2-Phenoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-73-3P, 4-(2-Fluorobiphenyl-4-yl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-74-4P, 4-[4-(4-(Tetrahydropyran-2-yl)oxy)phenyl]thieno[2,3-c]pyridine-2-carboxamide  
 870237-75-5P, 4-(4-Benzoyloxyphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-76-6P, 4-(2-Benzoyloxyphenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-77-7P, 4-(4-Acetylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-78-8P, 4-[1-(Phenylsulfonyl)-1H-indol-3-yl]thieno[2,3-c]pyridine-2-carboxamide  
 870237-80-2P, 2-(1H-Tetrazol-5-yl)-4-(3-trifluoromethylphenyl)thieno[2,3-c]pyridine  
 870237-81-3P, 4-(3,5-Dichlorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-82-4P, 4-(3,4-Dimethoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-83-5P, 4-(5-Fluoro-2-methoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-84-6P, 2-(1H-Tetrazol-5-yl)-4-(4-trifluoromethoxyphenyl)thieno[2,3-c]pyridine  
 870237-85-7P, [4-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]methanol  
 870237-86-8P, N-[4-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]acetamide  
 870237-87-9P, 4-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenol  
 870237-88-0P, 4-(3-Isopropoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-89-1P, 3-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenol  
 870237-90-4P, 4-(2-Benzoyloxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-91-5P, 4-(Pyridin-4-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-92-6P, 4-[1-(Phenylsulfonyl)-1H-indol-3-yl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-93-7P, 4-(3,4-Dihydro-2H-benzo[b]dioxepin-7-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-94-8P, 4-(Biphenyl-4-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-95-9P, 4-(2-Fluorobiphenyl-4-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870237-96-0P, 1-[4-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]ethanone  
 870237-97-1P, 7-Amino-4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide  
 870237-98-2P, 2-(1H-Tetrazol-5-yl)-4-(2-methylphenyl)thieno[2,3-c]pyridine  
 870237-99-3P, 4-(2-Chlorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870238-00-9P, 4-(Benzodioxol-5-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870238-01-0P, 4-(4-Methoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870238-02-1P, 2-(1H-Tetrazol-5-yl)-4-(2-trifluoromethoxyphenyl)thieno[2,3-c]pyridine  
 870238-03-2P, 4-(2,3-Dihydrobenzofuran-5-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 870238-04-3P, 2-(1H-Tetrazol-5-yl)-4-(4-methylphenyl)thieno[2,3-c]pyridine  
 870238-05-4P, [3-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]methanol  
 870238-06-5P, 2-(1H-Tetrazol-5-yl)-4-(3-trifluoromethoxyphenyl)thieno[2,3-c]pyridine  
 870238-07-6P, 4-(Biphenyl-2-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870238-08-7P, 4-(2-Phenoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870238-09-8P, 4-(3-Nitrophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870238-10-1P, 4-[2-(1H-Tetrazol-5-yl)thieno[2,3-



c]pyridin-4-yl]quinoline 870238-11-2P, 4-(4-Chlorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-12-3P, 4-(3-Ethoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-13-4P, 4-(4-Methylsulfonylphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-14-5P, 4-(4-Benzoyloxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-15-6P, 4-(2-Fluoro-3-methoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-16-7P, 4-[4-[(Tetrahydropyran-2-yl)oxy]phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-17-8P, 4-Phenyl-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-18-9P, 4-(Biphenyl-4-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-19-0P, 870238-21-4P, 4-(4-Amino-3-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-22-5P, 4-(3-Fluorobiphenyl-4-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-23-6P, 4-(Thiophen-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-24-7P, 4-(4-Formylphenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-25-8P, 3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)benzoic acid 870238-26-9P, 4-(3-Cyanophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-27-0P, 4-(Naphthalen-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-28-1P, 4-(4-Phenoxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-29-2P, 4-(3-Benzoyloxyphenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-32-7P, 4-(3-Chloro-4-ethoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-33-8P, 4-(5-Chloro-2-methylphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-34-9P, 4-(5-Chloro-2-ethoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-35-0P, 4-(3-Chloro-4-methylphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-37-2P, 4-Chloro-2-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]benzaldehyde 870238-38-3P, (5-Methylbenzoxazol-2-yl)[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-42-9P, 4-Phenyl-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870238-43-0P, 4-(1-Methyl-1H-indol-5-yl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870238-44-1P, 4-(4'-Methoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870238-46-3P, 4-[[4-(Benzo[b]thiophen-3-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-47-4P, 2-(1H-Tetrazol-5-yl)-4-[(2',3',4'-trimethoxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870238-50-9P, 7-Amino-4-(4'-methylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-51-0P, 7-Amino-4-(3'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-52-1P, 7-Amino-4-(2'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-53-2P, 7-Amino-4-(2'-methylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870238-54-3P, 4-[(4'-Nitrobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-55-4P, 4-[(4'-Acetylaminobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-56-5P, 4-[(4'-Acetylaminobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-57-6P, 4-[(4'-Dimethylaminobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-58-7P, 4-[(4'-Aminobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-59-8P, 4-[(4'-Methylsulfonylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-60-1P, 4-[(4'-Fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-61-2P, 4-[(4'-Methoxymethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-62-3P, 4-[(4'-Cyano-3'-methylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-63-4P, 4-[(4'-Carbamoylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-66-7P, 4-[(4'-Ethynylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-68-9P, 4-[(4'-Cyano-3'-fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870238-69-0P, 7-Amino-4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-71-4P, 7-Amino-4-[4-[(phenylacetyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-72-5P, 7-Amino-4-[4-(3-phenylureido)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-73-6P, 7-Amino-4-(3-benzoylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-74-7P, 7-Amino-4-(4-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-75-8P, 7-Amino-4-[4-[(benzoxazol-2-yl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-76-9P, 4-[3-[(3-Tolylsulfonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide



870238-77-0P, 4-[3-[[2-Chloro-4-trifluoromethylphenyl)sulfonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-78-1P, 4-[3-[(Thien-2-ylsulfonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-79-2P, 3-Methyl-N-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]benzenesulfonamide 870238-80-5P, 4-[4-[(3-Tolylsulfonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-81-6P, 4-[4-[(Phenylsulfonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-83-8P, 4-[[1-(Phenylsulfonyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870238-85-0P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]methanesulfonamide 870238-86-1P 870238-87-2P, [2-[[3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)phenyl]amino]ethyl]carbamic acid tert-butyl ester 870238-88-3P, 4-[3-[(Pyridin-4-ylmethyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-89-4P, 4-(3-Benzylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-90-7P, (Cyclopropylmethyl)[3-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-91-8P, (Cyclopropylmethyl)[4-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-92-9P, [(Pyridin-2-yl)methyl][3-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-93-0P, [(Pyridin-3-yl)methyl][3-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]amine 870238-94-1P, 4-(3-Phenethylaminophenyl)thieno[2,3-c]pyridine-2-carboxamide 870238-95-2P, 4-[3-(3-Phenylpropylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-96-3P, 4-[3-[(2-Methoxybenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-97-4P, 4-[3-[(3-Methoxybenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-98-5P, 4-[3-[(4-Methoxybenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870238-99-6P, 4-[3-[(2-Chlorobenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-00-2P, 4-[3-[(3-Chlorobenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-01-3P, 4-[3-[(4-Chlorobenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-02-4P, 4-[3-[(2-Trifluoromethylbenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-03-5P, 4-[3-[(3-Trifluoromethylbenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-04-6P, 4-[3-[(4-Trifluoromethylbenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-05-7P, 4-[3-[(2,4-Dimethoxybenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-06-8P, 4-[3-[(2,4-Dichlorobenzyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-07-9P, 4-[3-[[2,3-Dihydrobenzo[1,4]dioxin-6-yl)methyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-08-0P, 4-[3-(3-Cyclopentylureido)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-09-1P, 4-[3-[3-(2-Fluoro-5-trifluoromethylphenyl)ureido]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-10-4P, 1-[3-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(m-tolyl)urea 870239-11-5P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(m-tolyl)urea 870239-12-6P, 1-Phenyl-3-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]urea 870239-13-7P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(o-tolyl)urea 870239-14-8P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(p-tolyl)urea 870239-15-9P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(2-trifluoromethylphenyl)urea 870239-16-0P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 870239-17-1P, 1-[4-[2-(2H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]-3-(4-trifluoromethylphenyl)urea 870239-18-2P, 1-(2,5-Dichlorophenyl)-3-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]urea 870239-19-3P, 1-(3,5-Dichlorophenyl)-3-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]urea 870239-20-6P, 1-(2,6-Dichlorophenyl)-3-[4-[2-(2H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]urea 870239-21-7P, 4-[4-(3-Phenylureido)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-22-8P, 4-[4-[3-(3-Trifluoromethylphenyl)ureido]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-23-9P, 4-[4-(3-Isopropylureido)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-25-1P, 4-[[1-[(Phenylthio)carbamoyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-26-2P,

4-[[1-[(3,4-Dimethoxyphenyl)carbamoyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-27-3P, 1-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]-3-ethylurea 870239-28-4P, 1-Ethyl-3-[4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]urea 870239-29-5P, 4-[3-(2-Fluoro-4-trifluoromethylbenzoylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-30-8P, 4-[3-(3-Trifluoromethylbenzoylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-31-9P, 4-[3-[(Thien-2-yl)carbonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-32-0P, 4-[4-(3-Trifluoromethylbenzoylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-33-1P, 4-(4-Benzoylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-34-2P, 4-(4-Isobutanoylamino)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870239-35-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid (3-hydroxypropyl)amide 870239-38-6P 870239-39-7P, 4-[[4-[(Piperidin-4-yl)carbamoyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-40-0P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid dimethylamide 870239-41-1P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid methylamide 870239-42-2P, 4-[[4-(4-Cyanophenylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-43-3P, 4-[[4-[(3,4-Dimethoxyphenyl)carbamoyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-44-4P, 4-[[4-(3-Cyanophenylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-45-5P, 4-[[4-(4-Sulfamoylphenylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-46-6P, 4-[[4-(Isopropylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-47-7P, 4-[[4-(Benzylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-48-8P, 3-[4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]benzoylamino]azetidine-1-carboxylic acid tert-butyl ester 870239-49-9P, 4-[[4-(Cyclohexylcarbamoyl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-51-3P 870239-52-4P, 4-[[4-[(2-Methylsulfanylethyl)carbamoyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-53-5P, 4-[[4-[Methyl(2-methylsulfanylethyl)carbamoyl]phenyl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-55-7P, 4-[(1-Benzoylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870239-56-8P, 4-[[1-(Phenylacetyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-57-9P, 4-[[1-(3-Phenylpropionyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-58-0P, 4-[[1-(3-Cyanobenzoyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-59-1P, 4-[[1-(4-Methoxybenzoyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-60-4P, 4-[[1-(2-Methoxybenzoyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-61-5P, 4-[[1-[(Pyridin-2-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-62-6P, 4-[[1-[(Pyridin-3-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-63-7P, 4-[[1-[(Pyridin-4-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-64-8P, 4-[[1-(2-Dimethylaminoacetyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-65-9P, 4-[[1-[(Isoxazol-5-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-66-0P, 4-[[1-[(Benzodioxol-5-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-67-1P, 4-[[1-[(Thien-2-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-68-2P, 4-[[1-[2-(2-Methoxyethoxy)acetyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-69-3P, 4-[[1-[(3,5-Dimethylisoxazol-4-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-70-6P, 4-[4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]piperidin-1-yl]-4-oxobutanoic acid methyl ester 870239-71-7P, 4-[[1-[(1-Acetylpiperidin-4-yl)carbonyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-72-8P, 4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]piperidine-1-carboxylic acid phenyl ester 870239-73-9P, 4-[[1-(Trifluoromethylacetyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-74-0P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]acetamide

870239-75-1P 870239-76-2P, N-[4-([2,2']Bithiophenyl-5-yl)-3-(2,2,2-trifluoroacetyl)thieno[2,3-c]pyridin-2-yl]-2,2,2-trifluoroacetamide  
 870239-78-4P, N-[4-(4'-Methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]acetamide 870239-79-5P, 2,2,2-Trifluoro-N-[4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]acetamide 870239-80-8P,  
 2-Methoxy-N-[4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]acetamide 870239-81-9P, Acetic acid [[4-([2,2']bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]carbamoyl]methyl ester 870239-82-0P,  
 N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]oxalamic acid ethyl ester 870239-83-1P, Isoxazole-5-carboxylic acid  
 N-[4-([2,2']bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]amide 870239-84-2P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]-2-dimethylaminoacetamide 870239-85-3P, 4-[[4'-(Butylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-86-4P,  
 4-[[4'-(Methylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-87-5P, 4-[[4'-(Dimethylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-88-6P,  
 4-[[4'-(Isopropylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-89-7P, 4-[[4'-(2-Hydroxyethylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-90-0P,  
 4-[[4'-(3-Hydroxypropylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-91-1P, 4-[[4'-(2-Ethylaminoethyl)carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-92-2P,  
 4-[[4'-(2-Diethylaminoethyl)carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-93-3P, 4-[[4'-(2-(Morpholin-4-yl)ethyl)carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-94-4P, 4-[[4'-(Piperazin-1-yl)carbonyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-95-5P,  
 4-[[4'-(4-Methylpiperazin-1-yl)carbonyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-96-6P, 4-[[4'-(Morpholin-4-yl)carbonyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-97-7P, 4-[[4'-(2-Methoxyethylcarbamoyl)biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-98-8P,  
 4-[[4'-(3-(Pyrrolidin-1-yl)propyl)carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870239-99-9P, 4-[[4'-(2-(Pyrrolidin-1-yl)ethyl)carbamoyl]biphenyl-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870240-00-9P, [4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridin-2-yl]carbamic acid tert-butyl ester 870240-01-0P, [4-(3-Chlorophenyl)thieno[2,3-c]pyridin-2-yl]carbamic acid tert-butyl ester 870240-03-2P, [4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]carbamic acid tert-butyl ester 870240-05-4P,  
 N-[4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridin-2-yl]-2,2,2-trifluoroacetamide 870240-06-5P, [4-((4'-Chlorobiphenyl-4-yl)oxy)thieno[2,3-c]pyridin-2-yl]amine 870240-07-6P,  
 N-[4-((4'-Chlorobiphenyl-4-yl)oxy)thieno[2,3-c]pyridin-2-yl]acetamide 870240-08-7P, [3-[4-((4'-Chlorobiphenyl-4-yl)oxy)thieno[2,3-c]pyridin-2-yl]ureido]acetic acid ethyl ester 870240-09-8P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid (2-hydroxyethoxy)amide 870240-12-3P, 4-[4-((Piperidin-4-yl)carbonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870240-15-6P, 7-Amino-4-(3'-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid trifluoroacetate 870240-17-8P,  
 7-Amino-4-(4'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid acetate 870240-19-0P 870240-20-3P, 4-[4-(2-Phenylaminoacetyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870240-21-4P, 4-[[3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)phenyl]carbamoyl]piperidine-1-carboxylic acid tert-butyl ester 870240-22-5P, 4-[3-[(1-Methylcyclopropylcarbonyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870240-23-6P, 4-[4-(Isopropylcarbamoyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870240-24-7P 870240-25-8P, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic acid N-(benzyloxy)amide 870240-26-9P 870240-27-0P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]piperidin-1-ylmethanone

870240-28-1P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl] (4-methylpiperazin-1-yl)methanone 870240-29-2P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl] (morpholin-4-yl)methanone 870240-30-5P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid N-(pyridin-4-yl)amide 870240-32-7P 870240-34-9P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [3-(morpholin-4-yl)propyl]amide diacetate 870240-35-0P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid propylamide 870240-36-1P, 4-[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]piperazin-2-one 870240-37-2P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid (2-aminoethyl)amide 870240-38-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid (2-dimethylaminoethyl)amide 870240-41-8P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid allyloxyamide 870240-42-9P 870240-43-0P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid isobutoxyamide 870240-44-1P, (2S)-2-[[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]-3-tert-butoxypropionic acid tert-butyl ester 870240-45-2P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(5-chloro-1,2,3-thiadiazol-4-yl)methoxy]amide 870240-46-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(4-methylbenzyl)oxy]amide 870240-47-4P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(2-chlorobenzyl)oxy]amide 870240-48-5P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(3-chlorobenzyl)oxy]amide 870240-49-6P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(2-methoxybenzyl)oxy]amide 870240-50-9P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(3-methoxybenzyl)oxy]amide 870240-51-0P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid methoxyamide 870240-53-2P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid [(4-methoxybenzyl)oxy]amide 870240-54-3P, 4-[(Biphenyl-3-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-55-4P, 4-(3-Phenoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-56-5P, 4-[(3-tert-Butylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-57-6P, 4-[(2-tert-Butylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-58-7P, 4-[(4-tert-Butylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-59-8P 870240-60-1P, 2-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]fluoren-9-one 870240-61-2P, 4-[[3-(Morpholin-4-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-62-3P, 4-[(4-Cyclopentylphenyl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870240-63-4P, 4-[(4-Cyclopentylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-64-5P, 4-(4-Phenoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-65-6P  
, 4-(2-Isopropoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-66-7P, 4-[(2-Cyclopentylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-67-8P, 4-(3-Isopropyl-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-68-9P, 4-(2-tert-Butyl-4-ethylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-69-0P, 4-[4-(1-Methyl-1-phenylethyl)phenoxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-70-3P 870240-71-4P, 5-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]isoquinoline 870240-72-5P, 4-[(5,6,7,8-Tetrahydronaphthalen-1-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)  
IT 870240-73-6P, 4-(4-Chloro-3-ethyl-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-74-7P, 4-[[4-(Indan-1-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-75-8P,

4-(2-Ethyl-4,5-dimethylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870240-76-9P, 4-(3-Ethyl-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870240-77-0P, 4-(2-Benzyl-4-methylphenoxy)-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870240-78-1P, 4-(2-Methyl-4-  
 methylsulfanylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870240-79-2P, 4-[(5-tert-Butylbiphenyl-2-yl)oxy]-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870240-80-5P, [3-[[2-(1H-Tetrazol-5-  
 yl)thieno[2,3-c]pyridin-4-yl]oxy]phenyl]acetic acid methyl ester  
 870240-81-6P, 4-[(2-Isopropylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870240-82-7P, 4-[(2-sec-Butylphenyl)oxy]-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870240-83-8P, 4-[(2,3-Dimethylphenyl)oxy]-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870240-84-9P, 4-[(2,4-  
 Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870240-85-0P, 4-[(2,5-Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870240-86-1P, 4-[(2-Benzylphenyl)oxy]-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870240-87-2P, 4-[(2-Ethylphenyl)oxy]-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870240-88-3P, 4-(3-Cyanophenoxy)-2-  
 (1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870240-89-4P,  
 4-(3-Chlorophenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870240-90-7P, 4-(3-Methoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870240-91-8P, 4-[(3-Isopropylphenyl)oxy]-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870240-92-9P, 4-[(3,4-Dimethylphenyl)oxy]-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870240-93-0P, 4-[(3,5-  
 Dimethylphenyl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870240-94-1P, 4-(4-Chloro-2-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870240-95-2P, 4-(2,3-Dimethoxyphenoxy)-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870240-96-3P, 4-(3,5-Dimethoxyphenoxy)-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870240-97-4P, 4-(3,4-  
 Dimethoxyphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870240-98-5P, 4-(4-tert-Butyl-2-methylphenoxy)-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870240-99-6P, 4-(3-Benzoyloxyphenoxy)-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870241-00-2P, 4-(2-Ethoxy-4-  
 methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-01-3P,  
 4-(2-Isopropyl-5-methylphenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870241-02-4P, 4-[(Naphthalen-1-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870241-03-5P, 4-(3-Ethoxyphenoxy)-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870241-04-6P, 4-(2-Methoxy-5-methylphenoxy)-2-  
 (1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-05-7P,  
 3-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]benzoic acid methyl  
 ester 870241-06-8P, 4-[(2,6-Dimethylphenyl)oxy]-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870241-07-9P, 4-[(3-Ethylphenyl)oxy]-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870241-08-0P, 2-(1H-Tetrazol-5-yl)-4-  
 (m-tolyloxy)thieno[2,3-c]pyridine 870241-09-1P, 4-[[3-(Piperazin-1-  
 yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-10-4P,  
 4-[[3-(Piperidin-1-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870241-12-6P, 4-[3-[[2-(Naphthyl)amino]methyl]phenyl]thieno[2,  
 3-c]pyridine-2-carboxamide 870241-13-7P, 4-[3-[[3-  
 Hydroxyphenylamino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide  
 870241-14-8P, 4-[3-[[3-[(Quinolin-6-yl)amino]methyl]phenyl]thieno[2,3-  
 c]pyridine-2-carboxamide 870241-15-9P, 4-[3-[[4-tert-  
 Butylphenylamino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide  
 870241-16-0P, 4-[3-[[3-Chloro-4-fluorophenylamino]methyl]phenyl]thieno[2,3-  
 c]pyridine-2-carboxamide 870241-17-1P, 4-[3-  
 [(Benzylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide  
 870241-18-2P, 4-[3-[[3-(Pyridin-2-ylmethyl)amino]methyl]phenyl]thieno[2,3-  
 c]pyridine-2-carboxamide 870241-19-3P, 4-[3-[[2,2-  
 Diphenylethylamino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide  
 870241-20-6P, 4-[3-[[2-Hydroxyphenylamino]methyl]phenyl]thieno[2,3-  
 c]pyridine-2-carboxamide 870241-21-7P, 4-[3-[[3-  
 (Benzoyloxy)phenyl]amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide  
 870241-22-8P, 4-[3-[[3-(Phenylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-  
 carboxamide 870241-23-9P, 4-[3-[[2,3-Dihydroindol-1-  
 yl]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-24-0P,

4-[3-[[[Cyclohexylmethyl]amino]methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-25-1P, 4-[3-[(Phenethylamino)methyl]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-27-3P, 1-[2-[[3-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)benzyl]amino]ethyl]pyrrolidinium acetate 870241-29-5P 870241-31-9P 870241-32-0P, Biphenyl-4-yl-[2-[(4-methylpiperazin-1-yl)methyl]thieno[2,3-c]pyridin-4-yl]amine 870241-38-6P, 4-[[1-(2-Methylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-39-7P, 4-[[1-(3-Methylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-40-0P, 4-[[1-(4-Methylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-41-1P, 4-[[1-(2-Cyanobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-42-2P, 4-[[1-(3-Cyanobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-43-3P, 4-[[1-(4-Cyanobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-44-4P, 4-[[1-(Cyclohexylmethyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-45-5P, 4-[[1-(Phenethylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870241-46-6P, 4-[[1-[(Pyridin-2-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-47-7P, 4-[[1-[(Pyridin-3-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-48-8P, 4-[[1-[(Pyridin-4-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-49-9P, 4-[[1-[(3H-Imidazol-4-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-50-2P, 4-[[1-[(1-Methyl-1H-benzimidazol-2-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-51-3P, 4-[[1-[(1-Oxopyridin-4-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-52-4P, 4-[[1-[(5-Hydroxymethylfuran-2-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-53-5P, 4-[[1-[(3-Methoxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-54-6P, 4-[[1-[(4-Methoxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-55-7P, 4-[[1-[(Benzodioxol-5-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-56-8P, 4-[[1-[[5-(2-Chlorophenyl)furan-2-yl]methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-57-9P, 4-[[1-[(4-Benzyloxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-58-0P, 4-[[1-(3,4-Dimethylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-59-1P, 4-[[1-[(Quinolin-2-yl)methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-60-4P, 4-[[1-(3,5-Dichlorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-61-5P, 4-[[1-[(2,5-Difluorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-62-6P, 4-[[1-(3,5-Dimethylbenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-63-7P, 4-[[1-[[5-(3-Chlorophenyl)furan-2-yl]methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-64-8P, 4-[[1-(2,6-Difluorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-65-9P, 4-[[1-(4-Phenoxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-66-0P, 4-[[1-(3,4-Dichlorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-67-1P, 4-[[1-[[5-(2-Trifluoromethylphenyl)furan-2-yl]methyl]piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-68-2P, 4-[[1-(2,3-Difluorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-69-3P, 4-[[1-(3,5-Difluorobenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-72-8P, 4-[(Biphenyl-4-yl)amino]-7-carbamimidoylthieno[2,3-c]pyridine-2-carboxamide 870241-73-9P, 7-Amino-4-(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870241-77-3P, N-[4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridin-2-yl]oxalamide 870241-78-4P, 4-[4-[[2-(4-Methylpiperazin-1-yl)acetyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-79-5P, 4-[4-[[2-(1,2,4-Triazol-1-yl)acetyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870241-80-8P, 4-[[1-(4-Nitrophenyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-

carboxamide 870241-81-9P, 4-[[1-(4,6-Dimethoxypyrimidin-2-yl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870241-82-0P, 4-[3-(Pyridin-3-yl)phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-87-5P, 2-(1H-Tetrazol-5-yl)-4-(6-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine 870241-88-6P, 4-(6-Fluorobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-89-7P, 4-(3'-Methylsulfonylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-90-0P, 4-(3'-Methoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-91-1P, 4-(2'-Methoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-92-2P, 4-(2'-Methylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-93-3P, 4-(3'-Nitrobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-94-4P, 4-(3'-Methylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-95-5P, 4-(4'-Fluorobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-96-6P, 4-(4'-Methylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-97-7P, 4-[3-(3,5-Dimethylisoxazol-4-yl)phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870241-98-8P, 3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-carbonitrile 870241-99-9P, 4-(4'-Methylsulfonylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-00-5P, [3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-yl]amine 870242-01-6P, 4-(2'-Fluorobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-02-7P, 1-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-yl]ethanone 870242-03-8P, 2-(1H-Tetrazol-5-yl)-4-(3'-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine 870242-04-9P, 1-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-yl]ethanone 870242-05-0P, 2-(1H-Tetrazol-5-yl)-4-(4'-trifluoromethylbiphenyl-3-yl)thieno[2,3-c]pyridine 870242-06-1P, 4-(3'-Fluorobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-07-2P, 4-(4'-tert-Butylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-08-3P, 4-(3',4'-Dimethoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-09-4P, Dimethyl[3'-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-yl]amine 870242-10-7P, 4-(4'-Ethylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-11-8P, 4-[3-(Benzo[b]thiophen-3-yl)phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-12-9P, 1-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-yl]methanol 870242-13-0P, 4-(3'-Cyanobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-14-1P, N-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-yl]methanesulfonamide 870242-15-2P, 3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-ol 870242-16-3P, 1-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-2-yl]methanol 870242-17-4P, 4-[3-(Furan-3-yl)phenyl]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-18-5P, 4-(3'-Methylsulfonylbiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-19-6P, 3-[3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]phenyl]thiophene-2-carboxaldehyde 870242-20-9P, 3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-carboxamide 870242-21-0P, [3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-yl]amine 870242-22-1P, Dimethyl[[3'-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-2-yl]methyl]amine 870242-23-2P, 4-(4'-Nitrobiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-24-3P, [3'-[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-2-yl]amine 870242-25-4P, Dimethyl[[3'-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-3-yl]methyl]amine 870242-26-5P, 4-(3'-Butoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-27-6P, 4-(4'-Butoxybiphenyl-3-yl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-28-7P, 3-Methoxy-3'-[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]biphenyl-4-ol 870242-29-8P, 7-Amino-4-(3'-methylsulfonylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-30-1P, 7-Amino-4-[3-(benzo[b]thiophen-3-yl)phenyl]thieno[2,3-c]pyridine-2-carboxamide 870242-31-2P, 7-Amino-4-(4'-ethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide 870242-32-3P, 7-Amino-4-(3'-methylbiphenyl-3-



yl)thieno[2,3-c]pyridine-2-carboxamide 870242-33-4P,  
 7-Amino-4-(3',4'-dimethoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-  
 carboxamide 870242-34-5P, 7-Amino-4-(3'-trifluoromethylbiphenyl-3-  
 yl)thieno[2,3-c]pyridine-2-carboxamide 870242-35-6P,  
 7-Amino-4-(3'-aminobiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxamide  
 870242-36-7P 870242-37-8P, 7-Amino-4-(4'-carbamoylebiphenyl-3-  
 yl)thieno[2,3-c]pyridine-2-carboxamide 870242-38-9P,  
 4-(4'-Acetylbiphenyl-3-yl)-7-aminothieno[2,3-c]pyridine-2-carboxamide  
 870242-39-0P, 7-Amino-4-(4'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-  
 carboxamide 870242-40-3P, 4-[(3'-Cyanobiphenyl-4-yl)oxy]thieno[2,3-  
 c]pyridine-2-carboxamide 870242-41-4P, 4-[[4-(Pyridin-4-  
 yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-42-5P,  
 4-[[4-(Thiophen-3-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide  
 870242-43-6P, 4-[[4-(Benzo[b]thiophen-3-yl)phenyl]oxy]thieno[2,3-  
 c]pyridine-2-carboxamide 870242-44-7P, 4-[(3',5'-Dichlorobiphenyl-4-  
 yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-45-8P,  
 4-[[4'-Trifluoromethylbiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-  
 carboxamide 870242-46-9P, 4-[[4'-Fluorobiphenyl-4-yl)oxy]thieno[2,3-  
 c]pyridine-2-carboxamide 870242-47-0P, 4-[[4'-Chlorobiphenyl-4-  
 yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-48-1P,  
 4-[(3'-Methoxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide  
 870242-49-2P, 4-[(2'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-  
 carboxamide 870242-50-5P, 4-[(3'-Chlorobiphenyl-4-yl)oxy]thieno[2,3-  
 c]pyridine-2-carboxamide 870242-51-6P, 4-[[4-(Benzodioxol-5-  
 yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-52-7P,  
 4-[[4-(Naphthalen-1-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870242-53-8P, 8-[[4-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-  
 4-yl]oxy]phenyl]quinoline 870242-54-9P, 4'-[[2-(1H-Tetrazol-5-  
 yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-3-carboxylic acid methyl ester  
 870242-55-0P, 2-(1H-Tetrazol-5-yl)-4-[(3'-trifluoromethoxybiphenyl-4-  
 yl)oxy]thieno[2,3-c]pyridine 870242-56-1P, 2-(1H-Tetrazol-5-yl)-4-[(3'-  
 trifluoromethylbiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870242-57-2P,  
 4-[(3'-Nitrobiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870242-58-3P, [4'-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-  
 yl]oxy]biphenyl-3-yl]acetonitrile 870242-59-4P, 2-(1H-Tetrazol-5-yl)-4-  
 [(4'-trifluoromethoxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine  
 870242-60-7P, 4'-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-  
 yl]oxy]biphenyl-4-carbonitrile 870242-61-8P, 4-[(3',4'-Difluorobiphenyl-  
 4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-62-9P,  
 2-(1H-Tetrazol-5-yl)-4-[(3',4',5'-trifluorobiphenyl-4-yl)oxy]thieno[2,3-  
 c]pyridine 870242-63-0P, 4-[(3',4'-Dichlorobiphenyl-4-yl)oxy]-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870242-64-1P, 4-[(4'-Fluoro-3'-  
 methylbiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870242-65-2P, 4-[(3'-Fluoro-4'-methoxybiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870242-66-3P, 4-[(4'-Methyl-3'-nitrobiphenyl-4-  
 yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-67-4P,  
 4'-[[2-(1H-Tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-3-  
 carboxamide 870242-68-5P, 4-[(3'-Chloro-4'-fluorobiphenyl-4-yl)oxy]-2-  
 (1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-69-6P,  
 4-[(Biphenyl-3-yl)oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-70-9P,  
 4-[[4-(Benzodioxol-5-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide  
 870242-71-0P, 4-[4-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)phenoxy]-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870242-72-1P, 4-[(3',4'-  
 Dimethoxybiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870242-73-2P, 4-[(2',3'-Dimethoxybiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870242-74-3P, 2-(1H-Tetrazol-5-yl)-4-[(3',4',5'-  
 trimethoxybiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870242-75-4P,  
 3-Methoxy-4'-[[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-  
 4-ol 870242-76-5P, 4-[(2',5'-Dimethoxybiphenyl-4-yl)oxy]-2-(1H-tetrazol-  
 5-yl)thieno[2,3-c]pyridine 870242-77-6P, 4-[(4'-Methylsulfonylbiphenyl-4-  
 yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-78-7P,  
 4-[(4'-Methylsulfonylbiphenyl-4-yl)oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-  
 c]pyridine 870242-79-8P, 4-[[4-[(Pyridin-3-yl)ethynyl]phenyl]oxy]thieno[



2,3-c]pyridine-2-carboxamide 870242-80-1P, 4-[4-(Phenylethynyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870242-81-2P, 4-[4-(Morpholin-4-yl)phenyl]oxy]-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-82-3P, 4-[4-(Morpholin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxylic acid 870242-83-4P, 4-[4-(Morpholin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-84-5P, 4-(4-Phenylaminophenoxy)thieno[2,3-c]pyridine-2-carboxamide 870242-85-6P, 4-[4-(Pyrrolidin-1-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-86-7P, 4-[4-[(Indan-5-yl)amino]phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870242-87-8P, 4-[4-(Cyclohexylamino)phenoxy]thieno[2,3-c]pyridine-2-carboxamide 870242-88-9P, 4-[3-(Morpholin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxylic acid 870242-89-0P, 4-[3-(Morpholin-4-yl)phenyl]oxy]thieno[2,3-c]pyridine-2-carboxamide 870242-90-3P, 4-[3-[[[Dimethylamino)sulfonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870242-91-4P, 4-[4-[[4,5-Dibromothien-2-yl)sulfonyl]amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870242-96-9P, 4-Amino-7-(biphenyl-3-yl)thieno[2,3-c]pyridine-3-carboxylic acid 870242-97-0P, 4-Phenylsulfonylthieno[2,3-c]pyridine-2-carboxamide 870242-98-1P, 4-Phenylsulfinylthieno[2,3-c]pyridine-2-carboxamide 870242-99-2P, 4-(Biphenyl-3-yl)-1H-pyrrolo[2,3-c]pyridine-2-carbonitrile 870243-09-7P, 4-(Biphenyl-3-yl)furo[2,3-c]pyridine-2-carboxylic acid 870243-11-1P, 3-[4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]-2H-[1,2,4]oxadiazol-5-one 870243-12-2P, 3-[4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]-2H-[1,2,4]thiadiazol-5-one 870243-14-4P, 3-[4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]-2H-[1,2,4]oxadiazol-5-one 870243-15-5P, 4-(4-Iodophenoxy)-2-(5-phenyl-1H-imidazol-2-yl)thieno[2,3-c]pyridine 870243-16-6P, [2-[4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]-3H-imidazol-4-yl]methanol 870243-17-7P, 2-(1H-Benzimidazol-2-yl)-4-[(biphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870243-19-9P, [3-[4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]ureido]acetic acid ethyl ester 870243-22-4P, 1-[4-(4-Iodophenoxy)thieno[2,3-c]pyridin-2-yl]-3-phenylurea 870243-23-5P, 4-Fluorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-24-6P, 4-Fluorothieno[2,3-c]pyridine-2-carboxylic acid N-(4-bromophenyl)amide 870243-25-7P, [4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]phenylmethanol 870243-26-8P, 2-(5-Benzyloxy)pyridin-3-yl)-4-[(biphenyl-4-yl)amino]thieno[2,3-c]pyridine 870243-30-4P, 4-[(Biphenyl-4-yl)amino]-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid 870243-32-6P, 7-Amino-4-[(biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxamide 870243-33-7P, 4-[(3',5'-Dichlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxylic hydrazide 870243-35-9P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]piperazin-1-ylmethanone 870243-36-0P, 870243-38-2P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid N-(tert-butoxy)amide 870243-40-6P, 3-[[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]propionic acid monotrifluoroacetate 870243-41-7P, (R)-2-[[[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]carbonyl]amino]-3-hydroxypropionic acid 870243-43-9P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]methanol 870243-44-0P, 4-[(4-Bromophenyl)(methyl)amino]thieno[2,3-c]pyridine-2-carboxamide 870243-45-1P, 4-Chlorobenzo[b]thiophene-2-carboxamide 870243-46-2P, 4-[(4'-Trifluoromethylbiphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870243-47-3P, 4,7-Bis(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870243-48-4P, 870243-50-8P, 4-[3-[(Carbamoylmethyl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 870243-52-0P, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid (2-dimethylaminoethyl)amide 870243-53-1P, 4-(4-Iodophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid

[3-(morpholin-4-yl)propyl]amide 870243-56-4P, [7-(Biphenyl-3-yl)thieno[3,2-c]pyridin-4-yl]amine 870243-57-5P, (Biphenyl-4-yl)[2-(2H-pyrazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-58-6P, Thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870243-60-0P, 4-[(Biphenyl-4-yl)amino]-7-phenylthieno[2,3-c]pyridine-2-carboxamide 870243-61-1P, 4-[(Biphenyl-4-yl)amino]-7-methylthieno[2,3-c]pyridine-2-carboxamide 870243-62-2P, 4-[(Biphenyl-4-yl)amino]-7-(1H-pyrrol-2-yl)thieno[2,3-c]pyridine-2-carboxamide 870243-63-3P, 4-[(Biphenyl-4-yl)amino]-7-carbamoylthieno[2,3-c]pyridine-2-carboxylic acid 870243-65-5P, 4-[(Biphenyl-4-yl)amino]-7-cyanothieno[2,3-c]pyridine-2-carboxylic acid 870243-69-9P, 4-[[5-(Pyridin-2-yl)thiophen-2-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870243-73-5P, (Biphenyl-4-yl)[2-(5-isopropylamino-[1,2,4]oxadiazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-74-6P 870243-77-9P, (Biphenyl-4-yl)[2-(4H-[1,2,4]triazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-78-0P 870243-80-4P, (Biphenyl-4-yl)[2-(5-trifluoromethyl-4H-[1,2,4]triazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-81-5P, 4-[4-[(Benzoxazol-2-yl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870243-82-6P, 4-[3-Fluoro-4-[(5-fluorobenzoxazol-2-yl)amino]phenyl]thieno[2,3-c]pyridine-2-carboxamide 870243-83-7P, (Biphenyl-4-yl)[2-(3H-[1,2,3]triazol-4-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-87-1P 870243-88-2P, 3-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-2-cyano-N-isopropyl-3-oxopropionamide 870243-90-6P, 5-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-3H-[1,3,4]oxadiazol-2-one 870243-91-7P, [2-(5-Amino-[1,3,4]oxadiazol-2-yl)thieno[2,3-c]pyridin-4-yl](biphenyl-4-yl)amine 870243-92-8P 870243-93-9P, [2-(5-Amino-2H-pyrazol-3-yl)thieno[2,3-c]pyridin-4-yl](biphenyl-4-yl)amine 870243-98-4P, 4-[[1-(2-Hydroxybenzyl)piperidin-4-yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870244-00-1P, 4-[[1-(Benzyloxycarbonyl)piperidin-4-yl]methyl]-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-03-4P, 7-Amino-4-bromothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-05-6P, 4-(4-Bromophenylamino)thieno[2,3-c]pyridine-2-carboxylic acid (2-hydroxy-1-methylethyl)amide 870244-07-8P, 4-[(4-Benzylpiperazin-1-yl)carbonyl]thieno[2,3-c]pyridine-2-carboxamide 870244-09-0P 870244-12-5P, 3-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-1,1-dimethylurea 870244-14-7P, 1-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-1,4-dihydrotetrazol-5-one 870244-15-8P, [4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]urea 870244-16-9P 870244-18-1P, 5-[(Biphenyl-4-yl)methyl]imidazo[1,2-a]pyrazine-2-carboxylic acid 870244-19-2P, 3-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-4H-[1,2,4]oxadiazin-5-one 870244-20-5P, 2-[4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridin-2-yl]-4H-[1,3,4]oxadiazin-5-one 870244-22-7P 870244-25-0P, 5-Amino-4-(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid 870244-31-8P, 4-(4-Bromophenylamino)-3-methylthieno[2,3-c]pyridine-2-carboxamide 870244-32-9P, 4-(4-Bromophenylamino)-3-methylthieno[2,3-c]pyridine-2-carboxylic acid 870244-33-0P 870244-36-3P, Biphenyl-4-yl-(1H-pyrrolo[2,3-c]pyridin-4-yl)amine 870244-39-6P, 4-(Biphenyl-3-yl)-1-(2-carboxyethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid 870244-40-9P, 4-(Biphenyl-3-yl)-1-(2-carbamoyl-ethyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 870239-24-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

IT 146838-30-4 150316-07-7

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; preparation of fused heterocycles as kinase inhibitors)

- IT 372092-80-3, Protein kinase  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; preparation of fused heterocycles as kinase, particularly COT and MK2 kinase, inhibitors)
- IT 19099-93-5P, 4-Oxopiperidine-1-carboxylic acid benzyl ester 32380-70-4P,  
 2-(2-Hydroxypropoxy)isoindole-1,3-dione 77112-52-8P 87597-27-1P,  
 5-Bromoimidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester  
 138163-12-9P, 4-Methylenepiperidine-1-carboxylic acid benzyl ester  
 158609-08-6P, 3-Chloro-5-(methoxymethoxy)pyridine 252663-49-3P,  
 [3-(Benzoylamino)phenyl]boronic acid 799293-91-7P, 4-Amino-3-bromo-7-  
 iodothieno[3,2-c]pyridine 819056-67-2P, 1-Phenyl-3-[4-(4,4,5,5-  
 tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]urea 870234-98-3P,  
 3,5-Difluoropyridine-4-carboxaldehyde 870235-14-6P 870235-23-7P,  
 4-(Biphenyl-3-yl)thieno[2,3-c]pyridine 870235-31-7P,  
 2-[(Benzyloxycarbonyl)amino]-3-(3,5-dibromopyridin-4-yl)acrylic acid  
 methyl ester 870235-35-1P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-  
 2-carboxylic acid N-methoxy-N-methylamide 870235-36-2P,  
 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine-2-carboxaldehyde  
 870238-70-3P, 2-Phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-  
 yl)phenyl]acetamide 870243-00-8P, 3-[(Biphenyl-4-yl)oxy]-5-bromopyridine-  
 4-carboxaldehyde 870243-01-9P, 2-[(Benzyloxycarbonyl)amino]-3-[3-  
 [(biphenyl-4-yl)oxy]-5-bromopyridin-4-yl]acrylic acid methyl ester  
 870243-03-1P, 3-Chloro-5-(methoxymethoxy)pyridine-4-carboxaldehyde  
 870243-04-2P, 5-Chloro-4-(dimethoxymethyl)pyridin-3-ol 870243-05-3P,  
 [[5-Chloro-4-(dimethoxymethyl)pyridin-3-yl]oxyl]acetic acid ethyl ester  
 870243-06-4P, [(5-Chloro-4-formylpyridin-3-yl)oxyl]acetic acid ethyl ester  
 870243-28-0P, 4-Bromo-5-chlorothieno[2,3-c]pyridine-2-carboxylic acid  
 methyl ester 870243-49-5P 870243-67-7P, 2-(2-tert-  
 Butoxyethoxy)isoindole-1,3-dione 870243-68-8P, 4-[[5-(Pyridin-2-  
 yl)thiophen-2-yl]amino]thieno[2,3-c]pyridine-2-carboxylic acid methyl  
 ester 870243-71-3P, (Biphenyl-4-yl)[2-(5-trichloromethyl-  
 [1,2,4]oxadiazol-3-yl)thieno[2,3-c]pyridin-4-yl]amine 870243-79-1P  
 870243-85-9P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic  
 acid methyl ester 870243-94-0P, (4-Bromothieno[2,3-c]pyridin-2-  
 yl)methanol 870243-95-1P, 4-Bromo-7-oxo-6,7-dihydrothieno[2,3-c]pyridine-  
 2-carboxylic acid methyl ester 870243-96-2P, 4-(Biphenyl-3-yl)-7-oxo-6,7-  
 dihydrothieno[2,3-c]pyridine-2-carboxylic acid 870244-01-2P,  
 4-Vinylthieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870244-02-3P  
 870244-08-9P 870244-10-3P, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-  
 2-carboxylic acid lithium salt 870244-13-6P, 4-[(Biphenyl-4-  
 yl)amino]thieno[2,3-c]pyridine-2-carbonyl chloride 870244-17-0P  
 870244-29-4P, 1-(3,5-Dibromopyridin-4-yl)ethanone 870244-35-2P  
 870244-38-5P, 4-Bromo-1-(2-methoxycarbonyl)ethyl)-1H-pyrrolo[2,3-c]pyridine-  
 2-carboxylic acid methyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of fused heterocycles as kinase inhibitors)
- IT 82249-72-7  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation of fused heterocycles as inhibitors of pErk signaling resulting  
 from lipopolysaccharides stimulation)
- IT 55-22-1, Isonicotinic acid, reactions 63-74-1, 4-Aminobenzenesulfonamide  
 64-04-0, Phenethylamine 67-36-7, 4-Phenoxybenzaldehyde 67-47-0,  
 5-Hydroxymethylfuran-2-carboxaldehyde 70-11-1, Bromoacetophenone  
 79-30-1, Isobutyryl chloride 86-58-8, Quinolin-8-ylboronic acid  
 86-77-1, 2-Dibenzofuranol 88-18-6, 2-tert-Butylphenol 88-69-7,  
 2-Isopropylphenol 89-72-5, 2-sec-Butylphenol 89-83-8, Thymol  
 89-98-5, 2-Chlorobenzaldehyde 90-00-6, 2-Ethylphenol 90-15-3,  
 1-Naphthol 90-43-7, Biphenyl-2-ol 91-59-8, Naphthalen-2-ylamine  
 92-67-1, Biphenyl-4-ylamine 92-69-3, Biphenyl-4-ol 94-09-7,  
 4-Aminobenzoic acid ethyl ester 95-54-5, o-Phenylenediamine, reactions  
 95-55-6, 2-Aminophenol 95-65-8, 3,4-Dimethylphenol 95-76-1,  
 3,4-Dichloroaniline 95-87-4, 2,5-Dimethylphenol 96-26-4,

Dihydroxyacetone 96-70-8, 2-tert-Butyl-4-ethylphenol 98-27-1,  
 4-tert-Butyl-2-methylphenol 98-54-4, 4-tert-Butylphenol 98-80-6,  
 Phenylboronic acid 99-92-3, 4'-Aminoacetophenone 99-98-9,  
 N,N-Dimethyl-p-phenylenediamine 100-01-6, 4-Nitroaniline, reactions  
 100-07-2, 4-Methoxybenzoyl chloride 100-36-7, N,N-Diethylethylenediamine  
 100-59-4, Phenylmagnesium chloride 103-01-5, N-Phenylglycine 103-71-9,  
 Phenyl isocyanate, reactions 103-80-0, Phenylacetyl chloride 104-53-0,  
 3-Phenylpropionaldehyde 104-85-8, 4-Methylbenzonitrile 104-87-0,  
 4-Methylbenzaldehyde 104-88-1, 4-Chlorobenzaldehyde, reactions  
 104-94-9, p-Anisidine 105-07-7, 4-Formylbenzonitrile 105-36-2, Ethyl  
 bromoacetate 105-67-9, 2,4-Dimethylphenol 106-40-1, 4-Bromophenylamine  
 106-47-8, 4-Chloroaniline, reactions 106-49-0, p-Toluidine, reactions  
 108-00-9, N,N-Dimethylethylenediamine 108-23-6, Isopropyl chloroformate  
 108-39-4, m-Cresol, reactions 108-43-0, 3-Chlorophenol 108-68-9,  
 3,5-Dimethylphenol 108-91-8, Cyclohexylamine, reactions 109-01-3,  
 1-Methylpiperazine 109-85-3, 2-Methoxyethylamine 109-90-0, Ethyl  
 isocyanate 110-72-5, N-Ethylethylenediamine 120-57-0,  
 1,3-Benzodioxole-5-carboxaldehyde 122-78-1, Phenylacetaldehyde  
 123-00-2, N-(3-Aminopropyl)morpholine 123-11-5, 4-Methoxybenzaldehyde,  
 reactions 135-02-4, 2-Methoxybenzaldehyde 139-59-3,  
 4-Phenoxyphenylamine 140-31-8, N-(2-Aminoethyl)piperazine 150-19-6,  
 3-Methoxyphenol 156-43-4 156-87-6, 3-Aminopropan-1-ol 288-13-1,  
 1H-Pyrazole 320-51-4, (4-Chloro-3-trifluoromethylphenyl)amine  
 329-01-1, 1-Isocyanato-3-trifluoromethylbenzene 350-46-9,  
 1-Fluoro-4-nitrobenzene 367-21-5, 3-Chloro-4-fluoroaniline 367-24-8,  
 4-Bromo-2-fluoroaniline 371-40-4, 4-Fluoroaniline 393-11-3,  
 5-Amino-2-nitrobenzotrifluoride 437-81-0, 2,6-Difluorobenzaldehyde  
 447-61-0, 2-Trifluoromethylbenzaldehyde 454-89-7, 3-  
 Trifluoromethylbenzaldehyde 455-14-1, 4-Aminobenzotrifluoride  
 455-19-6, 4-Trifluoromethylbenzaldehyde 461-82-5, 4-  
 (Trifluoromethoxy)aniline 496-15-1, Indoline 500-22-1,  
 3-Pyridinecarboxaldehyde 500-99-2, 3,5-Dimethoxyphenol 504-24-5,  
 Pyridin-4-ylamine 524-38-9, 2-Hydroxyisoindole-1,3-dione 526-75-0,  
 2,3-Dimethylphenol 529-19-1, 2-Methylbenzonitrile 529-20-4,  
 2-Methylbenzaldehyde 529-35-1, 5,6,7,8-Tetrahydro-1-naphthol 536-74-3,  
 Phenylacetylene 539-74-2, 3-Bromopropionic acid ethyl ester 540-38-5,  
 4-Iodophenol 576-26-1, 2,6-Dimethylphenol 577-92-4,  
 4-tert-Butyl-2-phenylphenol 580-15-4, 6-Aminoquinoline 583-75-5,  
 (4-Bromo-2-methylphenyl)amine 585-34-2, 3-tert-Butylphenol 587-04-2,  
 3-Chlorobenzaldehyde 589-16-2, 4-Ethylaniline 591-27-5, 3-Aminophenol  
 591-31-1, 3-Methoxybenzaldehyde 591-54-8, 4-Aminopyrimidine 599-64-4,  
 4-Cumylphenol 613-45-6, 2,4-Dimethoxybenzaldehyde 614-68-6, o-Tolyl  
 isocyanate 618-45-1, 3-Isopropylphenol 620-17-7, 3-Ethylphenol  
 620-22-4, 3-Methylbenzonitrile 620-23-5, 3-Methylbenzaldehyde  
 621-29-4, m-Tolyl isocyanate 621-34-1, 3-Ethoxyphenol 622-58-2,  
 p-Tolyl isocyanate 625-92-3, 3,5-Dibromopyridine 645-45-4,  
 3-Phenylpropionyl chloride 656-65-5, 4-Bromo-3-fluoroaniline 698-71-5,  
 3-Ethyl-5-methylphenol 713-68-8, 3-Phenoxyphenol 716-96-1,  
 2-Benzyl-4-methylphenol 768-35-4, 3-Fluorophenylboronic acid 769-92-6,  
 4-tert-Butylaniline 782-45-6, 4-Aminobenzanilide 831-82-3,  
 4-Phenoxyphenol 872-85-5, 4-Pyridinecarboxaldehyde 873-62-1,  
 3-Cyanophenol 873-74-5, 4-Aminobenzonitrile 874-42-0,  
 2,4-Dichlorobenzaldehyde 876-33-5 1121-60-4, 2-Pyridinecarboxaldehyde  
 1125-66-2, 4-Chloro-3-ethyl-5-methylphenol 1138-52-9,  
 3,5-Di-tert-butylphenol 1195-09-1, 2-Methoxy-5-methylphenol 1423-26-3,  
 (3-Trifluoromethylphenyl)boronic acid 1484-26-0, 3-Benzyloxyaniline  
 1489-69-6, Cyclopropanecarboxaldehyde 1490-25-1, 3-  
 Chlorocarbonylpropionic acid methyl ester 1518-83-8, 4-Cyclopentylphenol  
 1518-84-9, 2-Cyclopentylphenol 1520-21-4, 4-Aminostyrene 1548-13-6,  
 1-Isocyanato-4-trifluoromethylbenzene 1570-64-5, 4-Chloro-2-methylphenol  
 1679-18-1, 4-Chlorophenylboronic acid 1692-15-5, Pyridin-4-ylboronic  
 acid 1692-25-7, Pyridin-3-ylboronic acid 1711-11-1, 3-Cyanobenzoyl  
 chloride 1765-93-1, 4-Fluorophenylboronic acid 1795-48-8, Isopropyl

isocyanate 1885-14-9, Phenyl chloroformate 1899-93-0,  
 m-Toluenesulfonyl chloride 1993-03-9, 2-Fluorophenylboronic acid  
 2033-89-8, 3,4-Dimethoxyphenol 2038-03-1, N-(2-Aminoethyl)morpholine  
 2043-61-0, Cyclohexanecarboxaldehyde 2219-78-5, 3,4-Dimethyl-6-  
 ethylphenol 2221-00-3, [4-(Imidazol-1-yl)phenyl]amine 2237-30-1,  
 3-Aminobenzonitrile 2243-47-2, [1,1'-Biphenyl]-3-amine 2251-65-2,  
 m-(Trifluoromethyl)benzoyl chloride 2285-12-3, 1-Isocyanato-2-  
 trifluoromethylbenzene 2359-60-6, 4-(Piperidin-1-yl)phenylamine  
 2365-48-2, Methyl thioglycolate 2439-04-5, 5-Hydroxyisoquinoline  
 2510-23-8, 3-Ethynylpyridine 2524-67-6, 4-(Morpholin-4-yl)phenylamine  
 2563-07-7, 2-Ethoxy-4-methylphenol 2646-91-5, 2,3-Difluorobenzaldehyde  
 2687-43-6, O-Benzylhydroxylamine hydrochloride 2759-28-6,  
 1-Benzylpiperazine 2949-22-6, Isocyanatoacetic acid ethyl ester  
 2963-77-1, 4-(1H-Benzimidazol-2-yl)phenylamine 3012-80-4,  
 1-Methyl-1H-benzimidazole-2-carboxaldehyde 3034-50-2,  
 3H-Imidazole-4-carboxaldehyde 3218-02-8, Aminomethylcyclohexane  
 3228-03-3, 5-Isopropyl-3-methylphenol 3544-25-0, 4-Aminobenzyl cyanide  
 3586-12-7, 3-Phenoxyphenylamine 3731-51-9, 2-(Aminomethyl)pyridine  
 3769-41-3, 3-Benzyloxyphenol 3795-76-4 3839-39-2 3900-89-8,  
 2-Chlorophenylboronic acid 3963-62-0, 2,2-Diphenylethylamine  
 4347-31-3, (2-Formylthien-3-yl)boronic acid 4397-53-9,  
 4-Benzyloxybenzaldehyde 4469-80-1, 4-Propoxyphenylamine 4688-76-0,  
 Biphenyl-2-ylboronic acid 4747-71-1, Cyclopentyl isocyanate 4755-77-5,  
 Ethyl oxalyl chloride 4760-58-1 4812-20-8, 2-Isopropoxyphenol  
 4854-84-6, 4'-Aminobiphenyl-4-carbonitrile 5049-61-6, Aminopyrazine  
 5122-94-1, (1,1'-Biphenyl-4-yl)boronic acid 5122-95-2,  
 Biphenyl-3-ylboronic acid 5150-42-5, 2,3-Dimethoxyphenol 5192-03-0,  
 5-Aminoindole 5271-67-0, 2-Thiophenecarbonyl chloride 5392-82-5  
 5402-37-9, 4-(1-Indanyl)phenol 5555-48-6 5625-67-2, Piperazinone  
 5720-05-8, 4-Methylphenylboronic acid 5720-06-9, 2-Methoxyphenylboronic  
 acid 5720-07-0, 4-Methoxyphenylboronic acid 6084-58-8,  
 O-Isobutylhydroxylamine hydrochloride 6165-69-1, Thien-3-ylboronic acid  
 6287-38-3, 3,4-Dichlorobenzaldehyde 6315-89-5, 3,4-Dimethoxyphenylamine  
 6361-22-4, 2-Chloro-6-nitrobenzaldehyde 6373-50-8, (4-  
 Cyclohexylphenyl)amine 6914-76-7, 1-Methylcyclopropanecarboxylic acid  
 6949-73-1, 2-Hydroxyfluoren-9-one 7154-73-6, 1-(2-Aminoethyl)pyrrolidine  
 7216-42-4, N-Oxopyridine-4-carboxaldehyde 7468-67-9,  
 2-Formylbenzonitrile 7570-49-2, 5-Amino-2-methylindole 7580-85-0,  
 2-tert-Butoxyethanol 10199-50-5, (2-Methyl-5-phenyl-2H-pyrazol-3-  
 yl)amine 10365-98-7, 3-Methoxyphenylboronic acid 10400-19-8,  
 3-Pyridinecarbonyl chloride 13035-19-3, Piperidin-4-ylamine  
 13223-25-1, 2-Chloro-4,6-dimethoxypyrimidine 13258-63-4,  
 4-(2-Aminoethyl)pyridine 13296-04-3, 4-(Pyridin-4-yl)phenylamine  
 13331-27-6, 3-Nitrophenylboronic acid 13382-43-9, 5-Amino-2-  
 methylbenzothiazole 13922-41-3, Naphthalen-1-ylboronic acid  
 14047-29-1, 4-Carboxyphenylboronic acid 14254-57-0, 4-Pyridinecarbonyl  
 chloride 14268-66-7, 3,4-(Methylenedioxy)aniline 16024-55-8,  
 (2-Methoxyethoxy)acetyl chloride 16114-47-9, (3,5-Dimethylisoxazol-4-  
 yl)boronic acid 16419-60-6, o-Tolylboronic acid 16629-19-9,  
 2-Thiophenesulfonyl chloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of fused heterocycles as kinase inhibitors)

IT 17933-03-8, 3-Methylphenylboronic acid 18542-42-2, 2-  
 (Methylthio)ethylamine 19438-10-9, Methyl 3-hydroxybenzoate  
 19992-45-1, (4-Phenylcyclohexyl)amine 20291-99-0, tert-Butyl  
 thioglycolate 21485-78-9, Methyl[2-(methylsulfanyl)ethyl]amine  
 21615-34-9, 2-Methoxybenzoyl chloride 22013-33-8, 3,4-  
 Ethylenedioxyaniline 22236-10-8, 4-(Difluoromethoxy)aniline  
 23159-07-1, 1-(3-Aminopropyl)pyrrolidine 24067-17-2,  
 4-Nitrophenylboronic acid 24424-99-5, tert-Butoxycarbonyl anhydride  
 24425-40-9, 5-Aminoindan 24964-64-5, 3-Formylbenzonitrile 25054-53-9,  
 Benzodioxole-5-carbonyl chloride 25487-66-5, (3-Carboxyphenyl)boronic  
 acid 27292-49-5, 3-(Morpholin-4-yl)phenol 27292-50-8,

3-Piperidinophenol 27578-60-5, 1-(2-Aminoethyl)piperidine 28611-39-4,  
 [4-(N,N-Dimethylamino)phenyl]boronic acid 28994-41-4,  
 2-Hydroxydiphenylmethane 29236-47-3, 2-Bromoethyl pyruvate 29605-78-5  
 29668-44-8, 2,3-Dihydrobenzo[1,4]dioxin-6-carboxaldehyde 29745-44-6,  
 2-Pyridinecarbonyl chloride 30418-59-8, 3-Aminophenylboronic acid  
 31301-45-8, 3,5-Dimethylisoxazole-4-carbonyl chloride 32085-88-4,  
 3,5-Difluorobenzaldehyde 32316-92-0, Naphthalen-2-ylboronic acid  
 33421-40-8, (5-Phenylpyridin-2-yl)amine 34035-04-6, 5-(2-  
 Chlorophenyl)furan-2-carboxaldehyde 34893-92-0, 1,3-Dichloro-5-  
 isocyanatobenzene 36716-44-6 37527-66-5, 4-Isocyanato-1,2-  
 dimethoxybenzene 38870-89-2, 2-Methoxyacetyl chloride 38936-62-8  
 38945-21-0, O-Allylhydroxylamine hydrochloride 39684-28-1,  
 O-tert-Butylhydroxylamine hydrochloride 39920-37-1 40972-86-9,  
 (2,3-Dimethoxyphenyl)boronic acid 41253-21-8, 1,2,4-Triazole sodium salt  
 41463-83-6, Trifluoromethylacetyl chloride 41979-39-9, 4-Piperidone  
 hydrochloride 42058-59-3, (3-Hydroxyphenyl)acetic acid methyl ester  
 50541-93-0, (1-Benzylpiperidin-4-yl)amine 51067-38-0,  
 4-Phenoxyphenylboronic acid 51387-90-7, 2-(2-Aminoethyl)-1-  
 methylpyrrolidine 51537-21-4, O-tert-Butyl-L-serine tert-butyl ester  
 hydrochloride 51552-16-0, Dimethylaminoacetyl chloride 55552-70-0,  
 Furan-3-ylboronic acid 57260-71-6, tert-Butyl 1-piperazinecarboxylate  
 57688-34-3, (4'-Trifluoromethylbiphenyl-4-yl)amine 58620-93-2  
 59016-93-2, (4-Hydroxymethylphenyl)boronic acid 59084-16-1,  
 1-Acetylpiperidine-4-carbonyl chloride 59817-32-2, 1-(3-  
 Hydroxyphenyl)piperazine 62348-13-4, Isoxazole-5-carbonyl chloride  
 62368-29-0, 1-Acetyl-6-amino-2,3-dihydro-1H-indole 63019-97-6,  
 (2-Methylbiphenyl-4-yl)amine 63139-21-9, 4-Ethylphenylboronic acid  
 63503-60-6, 3-Chlorophenylboronic acid 63921-23-3, 1-Phenylpiperidin-4-  
 amine 66472-86-4, 3-Aminophenylboronic acid hemisulfate 67492-50-6,  
 (3,5-Dichlorophenyl)boronic acid 68792-12-1, 3-Isopropoxyphenol  
 69922-27-6, 2-Fluoro-5-(trifluoromethyl)phenyl isocyanate 70201-42-2,  
 3,5-Dibromopyridine-4-carboxaldehyde 71597-85-8, 4-Hydroxyphenylboronic  
 acid 71902-33-5, 3,5-Difluoropyridine 73183-34-3, Diboron pinacol  
 ester 74115-12-1, 3-Chloropyridin-5-ol 75315-63-8 80500-27-2,  
 4-Methyl-3-nitrophenylboronic acid 81606-31-7, 4,5-Dibromothiophene-2-  
 sulfonyl chloride 83947-56-2 84358-13-4, N-(tert-  
 Butoxycarbonyl)piperidine-4-carboxylic acid 85107-53-5,  
 [2-[(N,N-Dimethylamino)methyl]phenyl]boronic acid 85199-06-0,  
 (2,5-Dimethylphenyl)boronic acid 86732-22-1, 2-  
 Benzyloctahydropyrrolo[3,4-c]pyrrole 87120-72-7 87199-14-2,  
 (2-Hydroxymethylphenyl)boronic acid 87199-15-3, (3-  
 Hydroxymethylphenyl)boronic acid 87199-16-4, 3-Formylphenylboronic acid  
 87199-17-5, 4-Formylphenylboronic acid 87199-18-6, 3-  
 Hydroxyphenylboronic acid 88568-95-0, N-(Benzyloxycarbonyl)- $\alpha$ -  
 phosphonoglycine trimethyl ester 89415-43-0, 4-Aminophenylboronic acid  
 89711-08-0, tert-Butyl N-(2-oxoethyl)carbamate 90555-66-1,  
 3-Ethoxyphenylboronic acid 94098-56-3, 5-(2-Trifluoromethylphenyl)furan-  
 2-carboxaldehyde 94839-07-3, (3,4-Methylenedioxyphenyl)boronic acid  
 96901-92-7, (8-Benzyl-8-azabicyclo[3.2.1]oct-3-yl)amine 98437-23-1,  
 (Benzo[b]thien-2-yl)boronic acid 98437-24-2, (Benzo[b]furan-2-yl)boronic  
 acid 99769-19-4, 3-Methoxycarbonylphenylboronic acid 100444-43-7,  
 2,6-Dimethylbiphenyl-4-ol 105365-51-3 107099-99-0,  
 (2,5-Dimethoxyphenyl)boronic acid 108238-09-1, 2-Phenoxyphenylboronic  
 acid 110952-48-2, 4-Amino-2-[(dimethylamino)methyl]phenol 113893-08-6,  
 (Benzo[b]thien-3-yl)boronic acid 114474-28-1, 4-(1H-Pyrazol-4-  
 yl)phenylamine 121219-16-7, (2,3-Difluorophenyl)boronic acid  
 122775-35-3, (3,4-Dimethoxyphenyl)boronic acid 123088-59-5,  
 4-Aminocarbonylphenylboronic acid 123324-71-0, 4-tert-Butylphenylboronic  
 acid 123784-07-6, 2-(5-Bromothiophen-2-yl)pyridine 126747-14-6,  
 4-Cyanophenylboronic acid 126917-10-0, 2-Fluoro-4-trifluoromethylbenzoyl  
 chloride 128312-11-8, 3-Methylsulfanylphenylboronic acid 128796-39-4,  
 (4-Trifluoromethylphenyl)boronic acid 129271-98-3, [1-(Phenylsulfonyl)-  
 1H-indol-3-yl]boronic acid 130722-95-1, 3-Benzyloxy-5-bromopyridine

135884-31-0, [1-(tert-Butoxycarbonyl)pyrrol-2-yl]boronic acid  
 136590-83-5, 3,5-Dichloropyridine-4-carboxaldehyde 138642-62-3,  
 2-Cyanophenylboronic acid 139301-27-2, (4-Trifluoromethoxyphenyl)boronic  
 acid 139911-27-6, (4-Fluoro-3-methylphenyl)boronic acid 143418-49-9,  
 (3,4,5-Trifluorophenyl)boronic acid 144432-85-9, 3-Chloro-4-  
 fluorophenylboronic acid 146631-00-7, (4-Benzoyloxyphenyl)boronic acid  
 147081-49-0, (R)-3-Aminopyrrolidine-1-carboxylic acid tert-butyl ester  
 148355-75-3, [3-[(Methylsulfonyl)amino]phenyl]boronic acid 148839-33-2,  
 (5-Chloro-2-methylphenyl)boronic acid 149104-88-1, 4-  
 (Methylsulfonyl)phenylboronic acid 149104-90-5, 4-Acetylphenylboronic  
 acid 149507-26-6, (3-Fluoro-4-methoxyphenyl)boronic acid 150255-96-2,  
 3-Cyanophenylboronic acid 151169-75-4, (3,4-Dichlorophenyl)boronic acid  
 156682-54-1, (3-Benzoyloxyphenyl)boronic acid 160521-46-0,  
 3'-Bromobiphenyl-4-carbonitrile 164014-95-3, (1,4-Benzodioxan-6-  
 yl)boronic acid 168267-41-2, (3,4-Difluorophenyl)boronic acid  
 175205-54-6, 2-Chloro-4-trifluoromethylbenzenesulfonyl chloride  
 175676-65-0, [2-(Trifluoromethoxy)phenyl]boronic acid 175883-63-3,  
 (3-Chloro-4-methylphenyl)boronic acid 178305-99-2, (2-Fluorobiphenyl-4-  
 yl)boronic acid 179113-90-7, [3-(Trifluoromethoxy)phenyl]boronic acid  
 179897-94-0, 5-Fluoro-2-methoxyphenylboronic acid 182163-96-8,  
 (3,4,5-Trimethoxyphenyl)boronic acid 182281-01-2, 4-Hydroxyphenylboronic  
 acid tetrahydropyranyl ether 190661-29-1, (2-Benzoyloxyphenyl)boronic  
 acid 191171-55-8, 2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline  
 192182-55-1, (N-Methylindol-5-yl)boronic acid 193269-78-2,  
 3-Aminoazetidine-1-carboxylic acid tert-butyl ester 195062-61-4,  
 2-(4-Chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 197507-55-4,  
 8-Bromo-[1,6]naphthyridine-2-carboxylic acid 204841-19-0,  
 3-Acetylphenylboronic acid 214360-60-8 214360-73-3,  
 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamine 216019-28-2,  
 3-Isopropylphenylboronic acid 227305-69-3, (2,3-Dihydrobenzo[b]furan-5-  
 yl)boronic acid 251993-29-0, 4-(3-Bromophenoxy)thieno[2,3-c]pyridine-2-  
 carboxamide 251994-31-7, 4-(4-Aminophenoxy)thieno[2,3-c]pyridine-2-  
 carboxamide 251996-00-6, 4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-  
 carboxamide 251996-52-8, 4-(4-Iodophenoxy)thieno[2,3-c]pyridine-2-  
 carboxylic acid methyl ester 251997-23-6, 4-(3-Chlorophenyl)thieno[2,3-  
 c]pyridine-2-carboxylic acid methyl ester 269410-08-4,  
 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 269410-22-2,  
 2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol  
 279261-81-3, 3-Chloro-4-ethoxyphenylboronic acid 279261-89-1,  
 (3,4-Dihydro-2H-1,5-benzodioxepin-7-yl)boronic acid 317821-72-0  
 330793-73-2, (Benzoxazol-2-yl)[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-  
 2-yl)phenyl]amine 351422-73-6, (3-Aminocarbonylphenyl)boronic acid  
 352303-67-4, 2-Fluoro-3-methoxyphenylboronic acid 352534-81-7,  
 3-Butoxyphenylboronic acid 352534-86-2, 5-Chloro-2-ethoxyphenylboronic  
 acid 370881-68-8, (1R,5R)-3,6-Diazabicyclo[3.2.0]heptane-3-carboxylic  
 acid benzyl ester 373384-18-0, 3-(Methylsulfonyl)phenylboronic acid  
 396131-82-1 400605-33-6 443998-73-0, (3'-Cyanobiphenyl-4-yl)amine  
 461699-49-0, (5-Methylbenzoxazol-2-yl)[4-(4,4,5,5-tetramethyl-1,3,2-  
 dioxaborolan-2-yl)phenyl]amine 479719-88-5, 5-(4,4,5,5-Tetramethyl-1,3,2-  
 dioxaborolan-2-yl)-2,2'-bithiophene 499769-97-0 716324-44-6,  
 2-Benzyl-2,8-diazaspiro[4.5]decan-1-one 775351-54-7,  
 2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile  
 819849-22-4, [3-[(N,N-Dimethylamino)methyl]phenyl]boronic acid  
 834884-74-1, [4-(Thiophen-3-yl)phenyl]amine 862729-59-7,  
 (5-Fluorobenzoxazol-2-yl)[2-fluoro-4-(4,4,5,5-tetramethyl-  
 1,3,2-dioxaborolan-2-yl)phenyl]amine 870235-04-4, 4-(4-  
 Bromophenylamino)thieno[2,3-c]pyridine-2-carbonitrile 870235-26-0,  
 4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridine 870235-30-6,  
 4-[[4-(Thiophen-3-yl)phenyl]amino]thieno[2,3-c]pyridine-2-carboxylic acid  
 tert-butyl ester 870235-37-3, 4-[(Biphenyl-4-yl)oxy]thieno[2,3-  
 c]pyridine-2-carboxylic acid N-methoxy-N-methylamide 870235-39-5,  
 [4-[(Biphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-yl]amine 870235-47-5,  
 4-[(Biphenyl-4-yl)amino]-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid



methyl ester monotrifluoroacetate 870235-54-4, 4-(4-tert-Butylphenylamino)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-56-6, 3'-(7-Amino-2-carbamoylthieno[2,3-c]pyridin-4-yl)biphenyl-4-carboxylic acid methyl ester 870235-58-8, 7-Amino-4-(3',4'-dimethoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-60-2, 7-Amino-4-(4'-carbamoylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-62-4, 7-Amino-4-(4'-methoxybiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-64-6, 7-Amino-4-[3-(benzo[b]thiophen-3-yl)phenyl]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-66-8, 7-Amino-4-(4'-ethylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-68-0, 7-Amino-4-[3-(pyridin-4-yl)phenyl]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-70-4, 7-Amino-4-(3'-methylsulfonylbiphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-72-6, 4-([2,2']Bithiophenyl-5-yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-74-8, 5-[(Biphenyl-3-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870235-84-0, 4-[(3,5-Dimethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-86-2, 4-[(3-Fluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-88-4, 4-[(3-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-90-8, 4-[(3-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-92-0, 4-[(2-Trifluoromethylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-94-2, 4-[(3-Methylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-97-5, 4-[(2-Chlorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870235-99-7, 4-[(3,5-Difluorobiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870236-11-6, 4-[(3-Methoxybiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870236-13-8, 4-(3-Chlorophenylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-20-7, 4-(4-Hydroxyphenylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-22-9, 4-(4-Aminophenylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-24-1, 4-(2-Cyanothieno[2,3-c]pyridin-4-yl)benzoic acid 870236-30-9, 4-(Cyclohexylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-32-1, 4-(4-Phenylcyclohexylamino)thieno[2,3-c]pyridine-2-carbonitrile 870236-34-3, 4-[(1-Benzylpiperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870236-37-6, (1R,5R)-6-(2-Cyanothieno[2,3-c]pyridin-4-yl)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylic acid benzyl ester 870236-39-8, 4-[(4'-Formylbiphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile 870236-41-2, 4-[(2-Cyanothieno[2,3-c]pyridin-4-yl)amino]piperidine-1-carboxylic acid tert-butyl ester 870236-43-4, (R)-3-[(2-Cyanothieno[2,3-c]pyridin-4-yl)amino]pyrrolidine-1-carboxylic acid tert-butyl ester 870236-45-6, 4-((3AS,6aR)-5-Benzylhexahydropyrrolo[3,4-c]pyrrol-2-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-47-8, 4-(2-Benzyloctahydropyrrolo[3,4-c]pyridin-5-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-49-0, 4-(2-Benzyl-1-oxo-2,8-diazaspiro[4.5]decan-8-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-51-4, 4-(1-Oxo-2-phenyl-2,8-diazaspiro[4.5]decan-8-yl)thieno[2,3-c]pyridine-2-carbonitrile 870236-53-6, (1R,4S)-5-(2-Cyanothieno[2,3-c]pyridin-4-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 870236-59-2, 4-Bromothieno[2,3-c]pyridine-2-carboxylic acid tert-butyl ester 870237-33-5, (3aR,7aR)-2-Benzyloctahydropyrrolo[3,4-c]pyridine 870237-35-7, (1R,4S)-2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 870238-20-3, [2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamic acid 870238-36-1, 5-Chloro-2-formylphenylboronic acid 870238-40-7, 4-(Biphenyl-3-yl)-7-chlorothieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870238-41-8, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine 870238-45-2, 4-(4-Bromophenoxy)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870238-65-6, 4,4,5,5-Tetramethyl-2-[4-[(trimethylsilyl)ethynyl]phenyl]-1,3,2-dioxaborolane 870238-67-8, 2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile 870238-84-9 870239-36-4,



4-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]benzoic acid 870239-54-6,  
 4-[(Piperidin-4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic acid  
 870239-77-3, [4-(4'-Methoxybiphenyl-3-yl)thieno[2,3-c]pyridin-2-yl]amine  
 870240-04-3, N'-(4-tert-Butylphenyl)thieno[2,3-c]pyridine-2,4-diamine  
 870240-13-4, 7-Amino-4-(3'-trifluoromethylbiphenyl-3-yl)thieno[2,3-  
 c]pyridine-2-carboxylic acid tert-butyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of fused heterocycles as kinase inhibitors)

IT 870240-18-9, 7-Amino-4-(4'-cyanobiphenyl-3-yl)thieno[2,3-c]pyridine-2-  
 carboxylic acid tert-butyl ester 870240-39-4 870240-52-1,  
 O-(2-tert-Butylethyl)hydroxyamine 870241-70-6, 7-Amino-4-(biphenyl-3-  
 yl)thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 870241-75-1,  
 (1R,4S)-5-[(2-Carbamoylthieno[2,3-c]pyridin-4-yl)amino]-2,5-  
 diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester  
 870241-76-2, 4-Bromo-7-chlorothieno[2,3-c]pyridine-2-carboxamide  
 870241-83-1, 4-(3-Chlorophenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine  
 870241-84-2, 4-(3-Chloro-4-trifluoromethylphenyl)-2-(1H-tetrazol-5-  
 yl)thieno[2,3-c]pyridine 870241-85-3, 4-(3-Chloro-4-fluorophenyl)-2-(1H-  
 tetrazol-5-yl)thieno[2,3-c]pyridine 870241-86-4, 4-(3-Chloro-4-  
 methoxyphenyl)-2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridine 870242-93-6,  
 (3-Bromothieno[2,3-c]pyridin-4-yl)amine 870243-02-0,  
 (Z)-2-[(Benzyloxycarbonyl)amino]-3-[3-[(biphenyl-4-yl)oxy]-5-bromopyridin-  
 4-yl]-2-propenoic acid methyl ester 870243-21-3 870243-34-8,  
 2-[[4-[(3',5'-Dichlorobiphenyl-4-yl)oxy]thieno[2,3-c]pyridin-2-  
 yl]carbonyl]hydrazinecarboxylic acid tert-butyl ester 870243-42-8  
 870243-54-2, 4-(2-Carbamoylthieno[2,3-c]pyridin-4-yl)benzoic acid ethyl  
 ester 870243-55-3, [7-(Biphenyl-3-yl)-3-bromothieno[3,2-c]pyridin-4-  
 yl]amine 870243-59-7, 7-[(Biphenyl-4-yl)amino]-4-bromothieno[2,3-  
 c]pyridine-2-carboxylic acid methyl ester 870243-66-6 870243-72-4,  
 4-[(Biphenyl-4-yl)amino]-N-hydroxythieno[2,3-c]pyridine-2-carboximidamide  
 870243-76-8, 4-[(Biphenyl-4-yl)amino]thieno[2,3-c]pyridine-2-carbonitrile  
 870243-97-3 870243-99-5, 4-[[1-(2-Methoxybenzyl)piperidin-4-  
 yl]amino]thieno[2,3-c]pyridine-2-carboxamide 870244-04-5,  
 7-[(Benzhydrylidene)amino]-4-bromothieno[2,3-c]pyridine-2-carboxylic acid  
 methyl ester 870244-06-7 870244-21-6, N'-(2-Chloroacetyl)-4-[(Biphenyl-  
 4-yl)amino]thieno[2,3-c]pyridine-2-carboxylic hydrazide 870244-23-8,  
 (Ethylamino)[[[4-[(4-phenylphenyl)amino]thieno[2,3-c]pyridin-2-  
 yl]carbonyl]amino]amino]methanone 870244-34-1, 3,5-  
 Dibromoisonicotinonitrile

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of fused heterocycles as kinase inhibitors)

IT 870244-26-1P, 5-Chloro-4-(biphenyl-3-yl)thieno[2,3-c]pyridine-2-carboxylic  
 acid

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of fused heterocycles as kinase inhibitors)

ALL ANSWERS HAVE BEEN SCANNED


=> d cbib abs hitstr 1-2

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

2005:1240986 Document No. 144:22906 Preparation of fused heterocycle kinase  
 inhibitors for treatment of protein tyrosine kinase-related diseases.  
 Cusack, Kevin; Salmeron-Garcia, Jose-Andres; Gordon, Thomas D.; Barberis,  
 Claude E.; Allen, Hamish J.; Bischoff, Agnieszka K.; Ericsson, Anna M.;  
 Friedman, Michael M.; George, Dawn M.; Roth, Gregory P.; Talanian, Robert  
 V.; Thomas, Christine; Wallace, Grier A.; Wishart, Neil; Yu, Zhengtian  
 (Abbott Laboratories, USA). PCT Int. Appl. WO 2005110410 A2 20051124, 362  
 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
 BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,  
 FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR,  
 KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG,

NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English).  
 CODEN: PIXXD2. APPLICATION: WO 2005-US16903 20050513. PRIORITY: US 2004-571281P 20040514.

GI




AB The invention is related to the preparation of fused heterocycles of formula I [A, B = independently N, S, O, a bond, etc.; D = C, N, S, O, C:C; U, V, W = independently CH and derivs., N; Y = a bond, CONH2 and derivs., SO, etc.; Z = H, halo, CN, etc.; X1 = a bond, halo, O, SO, NHSO2, etc.; R1 = a bond, (un)substituted benzofuranyl, benzimidazolyl, pyrrolyl, etc.; when R1 is not a bond, then X2 = a bond, O, S, NHCO and derivs., aliphatic group, etc.; or when R1 = a bond, then X2 = a bond and R2 is not a bond; R2 = a bond or (un)substituted benzoxazolyl, Ph, etc.; with provisos; and with the exception of certain compds.], and their pharmaceutically acceptable salts as inhibitors of kinases, particularly COT or MK2 kinases. The invention is also related to the use of certain compds. I as inhibitors of angiogenic receptor tyrosine kinases. Thus, reacting 4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide with cyclopropanecarboxaldehyde gave thienopyridine II. All compds. I significantly inhibit either COT or MK2 at concns. of 50  $\mu$ M or below.

IT 870242-75-4P, 3-Methoxy-4'-[[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]biphenyl-4-ol  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (COT kinase inhibitor; preparation of fused heterocycles as kinase inhibitors)

RN 870242-75-4 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 3-methoxy-4'-[[2-(1H-tetrazol-5-yl)thieno[2,3-c]pyridin-4-yl]oxy]- (9CI) (CA INDEX NAME)



L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

2004:1154700 Document No. 142:75325 Epoxy compound and amine-cured epoxy resin product. Tanaka, Shinya; Takezawa, Yoshitaka; Takahashi, Hiroyuki (Sumitomo Chemical Company, Limited, Japan; Hitachi, Ltd.). PCT Int.

Appl. WO 2004113327 A1 20041229, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-JP8934 20040618.

PRIORITY: JP 2003-174545 20030619.

AB The epoxy compound, which can be converted into a cured epoxy resin product having liquid crystal properties is obtained by curing with amine (or phenol) curing agent. Since the cured epoxy resin product exhibits good heat conductivity, it is also useful as an insulating material requiring high heat releasability such as a printed circuit substrate and the like. An example resin precursor 2,6-bis[4-[4-(oxiranylmethoxy)phenyl]phenoxy]pyridine had m.p. 157-160°.


IT 815600-54-5P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(pyridine condensate epoxy compound and cured epoxy resin product)

RN 815600-54-5 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 4'--[(6-chloro-2-pyridinyl)oxy]- (9CI) (CA INDEX NAME)



IT 815600-55-6P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)


(reaction with epichlorohydrin; pyridine condensate epoxy compound and

10560891

cured epoxy resin product)

RN 815600-55-6 CAPLUS

CN [1,1'-Biphenyl]-4-ol, 4'-[[6-(4-hydroxyphenoxy)-2-pyridinyl]oxy]- (9CI)  
(CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 14:32:41 ON 16 MAY 2007)

L1 FILE 'REGISTRY' ENTERED AT 14:33:10 ON 16 MAY 2007  
STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:36:46 ON 16 MAY 2007

L2 FILE 'REGISTRY' ENTERED AT 14:37:38 ON 16 MAY 2007  
STRUCTURE UPLOADED

FILE 'STNGUIDE' ENTERED AT 14:38:22 ON 16 MAY 2007

L3 FILE 'REGISTRY' ENTERED AT 14:44:02 ON 16 MAY 2007  
STRUCTURE UPLOADED

L4 0 S L3

L5 0 S L3 FULL

FILE 'STNGUIDE' ENTERED AT 14:45:20 ON 16 MAY 2007

L6 FILE 'REGISTRY' ENTERED AT 14:49:07 ON 16 MAY 2007  
STRUCTURE UPLOADED

L7 0 S L6

L8 5 S L7 FULL

L9 FILE 'CAPLUS' ENTERED AT 14:50:31 ON 16 MAY 2007  
1 S L8

FILE 'STNGUIDE' ENTERED AT 14:52:57 ON 16 MAY 2007

L10 FILE 'REGISTRY' ENTERED AT 14:57:15 ON 16 MAY 2007  
STRUCTURE UPLOADED

L11 0 S L10

L12 4 S L10 FULL

L13 FILE 'CAPLUS' ENTERED AT 15:00:41 ON 16 MAY 2007  
2 S L12

=> sel an l13 2

E1 THROUGH E2 ASSIGNED

10560891

=> e# and L3

E# IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s e1-2 and L13

0 "142:75325"/AN

1 "2004:1154700"/AN

L14 1 ("142:75325"/AN OR "2004:1154700"/AN) AND L13

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

18.58

549.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.56

-2.34

FILE 'REGISTRY' ENTERED AT 15:05:29 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> tra rn

L15 TRANSFER L14 1- RN : 20 TERMS

L16 20 L15


=> d scan

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Pyridine, 2,6-dichloro-

MF C5 H3 Cl2 N

CI COM




10560891

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyridine, 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy] - (9CI)  
MF C35 H29 N O6  
CI COM

PAGE 1-A



PAGE 2-A




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN [1,1'-Biphenyl]-4-ol, 4',4'''-[(6-methyl-2,4-pyrimidinediyl)bis(oxy)]bis-  
(9CI)  
MF C29 H22 N2 O4

10560891




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN [1,1'-Biphenyl]-4-ol, 4'-[[6-(4-hydroxyphenoxy)-2-pyridinyl]oxy] - (9CI)

MF C23 H17 N O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1




L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]pyridine (9CI)


MF (C35 H29 N O6 . C10 H10 N2)x

CI PMS

CM 1





CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Oxirane, 2,2'-(1,3-phenylenebis(methyleneoxy[1,1'-biphenyl]-4',4'-  
 diyloxymethylene))bis- (9CI)  
 MF C38 H34 O6






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L16 20 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Pyridazine, 3,6-dichloro-  
 MF C4 H2 Cl2 N2  
 CI COM





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d brow  
 :1-20


L16 ANSWER 1 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 815600-61-4 REGISTRY  
 ED Entered STN: 18 Jan 2005  
 CN Oxirane, 2,2'-[1,3-phenylenebis(methyleneoxy[1,1'-biphenyl]-4',4'-  
 diyloxymethylene)]bis- (9CI) (CA INDEX NAME)  
 MF C38 H34 O6  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 2 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-60-3 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN [1,1'-Biphenyl]-4-ol, 4',4'''-[1,3-phenylenebis(methyleneoxy)]bis- (9CI)  
(CA INDEX NAME)  
MF C32 H26 O4  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L16 ANSWER 3 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-59-0 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN Benzenamine, 4,4'-methylenebis-, polymer with 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]pyridine (9CI) (CA INDEX NAME)  
MF (C29 H25 N O6 . C13 H14 N2)x  
CI PMS  
PCT Epoxy resin, Polyether, Polyether  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 815600-56-7  
CMF C29 H25 N O6




OCC1=CC=C(C=C1)C2=CC=CC=C2OC3=CC=CC=C3N=C4C=CC=CC45OC6=CC=CC=C6OC7=CC=CC=C7C8OC9=CC=CC=C9C10OC11=CC=CC=C11C12OC13=CC=CC=C13C14OC15=CC=CC=C15C16OC17=CC=CC=C17C18OC19=CC=CC=C19C20OC21=CC=CC=C21C22OC23=CC=CC=C23C24OC25=CC=CC=C25C26OC27=CC=CC=C27C28OC29=CC=CC=C29C30OC31=CC=CC=C31C32OC33=CC=CC=C33C34OC35=CC=CC=C35C36OC37=CC=CC=C37C38OC39=CC=CC=C39C40OC41=CC=CC=C41C42OC43=CC=CC=C43C44OC45=CC=CC=C45C46OC47=CC=CC=C47C48OC49=CC=CC=C49C50OC51=CC=CC=C51C52OC53=CC=CC=C53C54OC55=CC=CC=C55C56OC57=CC=CC=C57C58OC59=CC=CC=C59C60OC61=CC=CC=C61C62OC63=CC=CC=C63C64OC65=CC=CC=C65C66OC67=CC=CC=C67C68OC69=CC=CC=C69C70OC71=CC=CC=C71C72OC73=CC=CC=C73C74OC75=CC=CC=C75C76OC77=CC=CC=C77C78OC79=CC=CC=C79C80OC81=CC=CC=C81C82OC83=CC=CC=C83C84OC85=CC=CC=C85C86OC87=CC=CC=C87C88OC89=CC=CC=C89C90OC91=CC=CC=C91C92OC93=CC=CC=C93C94OC95=CC=CC=C95C96OC97=CC=CC=C97C98OC99=CC=CC=C99C100OC101=CC=CC=C101C102OC103=CC=CC=C103C104OC105=CC=CC=C105C106OC107=CC=CC=C107C108OC109=CC=CC=C109C110OC111=CC=CC=C111C112OC113=CC=CC=C113C114OC115=CC=CC=C115C116OC117=CC=CC=C117C118OC119=CC=CC=C119C120OC121=CC=CC=C121C122OC123=CC=CC=C123C124OC125=CC=CC=C125C126OC127=CC=CC=C127C128OC129=CC=CC=C129C130OC131=CC=CC=C131C132OC133=CC=CC=C133C134OC135=CC=CC=C135C136OC137=CC=CC=C137C138OC139=CC=CC=C139C140OC141=CC=CC=C141C142OC143=CC=CC=C143C144OC145=CC=CC=C145C146OC147=CC=CC=C147C148OC149=CC=CC=C149C150OC151=CC=CC=C151C152OC153=CC=CC=C153C154OC155=CC=CC=C155C156OC157=CC=CC=C157C158OC159=CC=CC=C159C160OC161=CC=CC=C161C162OC163=CC=CC=C163C164OC165=CC=CC=C165C166OC167=CC=CC=C167C168OC169=CC=CC=C169C170OC171=CC=CC=C171C172OC173=CC=CC=C173C174OC175=CC=CC=C175C176OC177=CC=CC=C177C178OC179=CC=CC=C179C180OC181=CC=CC=C181C182OC183=CC=CC=C183C184OC185=CC=CC=C185C186OC187=CC=CC=C187C188OC189=CC=CC=C189C190OC191=CC=CC=C191C192OC193=CC=CC=C193C194OC195=CC=CC=C195C196OC197=CC=CC=C197C198OC199=CC=CC=C199C200OC201=CC=CC=C201C202OC203=CC=CC=C203C204OC205=CC=CC=C205C206OC207=CC=CC=C207C208OC209=CC=CC=C209C210OC211=CC=CC=C211C212OC213=CC=CC=C213C214OC215=CC=CC=C215C216OC217=CC=CC=C217C218OC219=CC=CC=C219C220OC221=CC=CC=C221C222OC223=CC=CC=C223C224OC225=CC=CC=C225C226OC227=CC=CC=C227C228OC229=CC=CC=C229C230OC231=CC=CC=C231C232OC233=CC=CC=C233C234OC235=CC=CC=C235C236OC237=CC=CC=C237C238OC239=CC=CC=C239C240OC241=CC=CC=C241C242OC243=CC=CC=C243C244OC245=CC=CC=C245C246OC247=CC=CC=C247C248OC249=CC=CC=C249C250OC251=CC=CC=C251C252OC253=CC=CC=C253C254OC255=CC=CC=C255C256OC257=CC=CC=C257C258OC259=CC=CC=C259C260OC261=CC=CC=C261C262OC263=CC=CC=C263C264OC265=CC=CC=C265C266OC267=CC=CC=C267C268OC269=CC=CC=C269C270OC271=CC=CC=C271C272OC273=CC=CC=C273C274OC275=CC=CC=C275C276OC277=CC=CC=C277C278OC279=CC=CC=C279C280OC281=CC=CC=C281C282OC283=CC=CC=C283C284OC285=CC=CC=C285C286OC287=CC=CC=C287C288OC289=CC=CC=C289C290OC291=CC=CC=C291C292OC293=CC=CC=C293C294OC295=CC=CC=C295C296OC297=CC=CC=C297C298OC299=CC=CC=C299C300OC301=CC=CC=C301C302OC303=CC=CC=C303C304OC305=CC=CC=C305C306OC307=CC=CC=C307C308OC309=CC=CC=C309C310OC311=CC=CC=C311C312OC313=CC=CC=C313C314OC315=CC=CC=C315C316OC317=CC=CC=C317C318OC319=CC=CC=C319C320OC321=CC=CC=C321C322OC323=CC=CC=C323C324OC325=CC=CC=C325C326OC327=CC=CC=C327C328OC329=CC=CC=C329C330OC331=CC=CC=C331C332OC333=CC=CC=C333C334OC335=CC=CC=C335C336OC337=CC=CC=C337C338OC339=CC=CC=C339C340OC341=CC=CC=C341C342OC343=CC=CC=C343C344OC345=CC=CC=C345C346OC347=CC=CC=C347C348OC349=CC=CC=C349C350OC351=CC=CC=C351C352OC353=CC=CC=C353C354OC355=CC=CC=C355C356OC357=CC=CC=C357C358OC359=CC=CC=C359C360OC361=CC=CC=C361C362OC363=CC=CC=C363C364OC365=CC=CC=C365C366OC367=CC=CC=C367C368OC369=CC=CC=C369C370OC371=CC=CC=C371C372OC373=CC=CC=C373C374OC375=CC=CC=C375C376OC377=CC=CC=C377C378OC379=CC=CC=C379C380OC381=CC=CC=C381C382OC383=CC=CC=C383C384OC385=CC=CC=C385C386OC387=CC=CC=C387C388OC389=CC=CC=C389C390OC391=CC=CC=C391C392OC393=CC=CC=C393C394OC395=CC=CC=C395C396OC397=CC=CC=C397C398OC399=CC=CC=C399C400OC401=CC=CC=C401C402OC403=CC=CC=C403C404OC405=CC=CC=C405C406OC407=CC=CC=C407C408OC409=CC=CC=C409C410OC411=CC=CC=C411C412OC413=CC=CC=C413C414OC415=CC=CC=C415C416OC417=CC=CC=C417C418OC419=CC=CC=C419C420OC421=CC=CC=C421C422OC423=CC=CC=C423C424OC425=CC=CC=C425C426OC427=CC=CC=C427C428OC429=CC=CC=C429C430OC431=CC=CC=C431C432OC433=CC=CC=C433C434OC435=CC=CC=C435C436OC437=CC=CC=C437C438OC439=CC=CC=C439C440OC441=CC=CC=C441C442OC443=CC=CC=C443C444OC445=CC=CC=C445C446OC447=CC=CC=C447C448OC449=CC=CC=C449C450OC451=CC=CC=C451C452OC453=CC=CC=C453C454OC455=CC=CC=C455C456OC457=CC=CC=C457C458OC459=CC=CC=C459C460OC461=CC=CC=C461C462OC463=CC=CC=C463C464OC465=CC=CC=C465C466OC467=CC=CC=C467C468OC469=CC=CC=C469C470OC471=CC=CC=C471C472OC473=CC=CC=C473C474OC475=CC=CC=C475C476OC477=CC=CC=C477C478OC479=CC=CC=C479C480OC481=CC=CC=C481C482OC483=CC=CC=C483C484OC485=CC=CC=C485C486OC487=CC=CC=C487C488OC489=CC=CC=C489C490OC491=CC=CC=C491C492OC493=CC=CC=C493C494OC495=CC=CC=C495C496OC497=CC=CC=C497C498OC499=CC=CC=C499C500OC501=CC=CC=C501C502OC503=CC=CC=C503C504OC505=CC=CC=C505C506OC507=CC=CC=C507C508OC509=CC=CC=C509C510OC511=CC=CC=C511C512OC513=CC=CC=C513C514OC515=CC=CC=C515C516OC517=CC=CC=C517C518OC519=CC=CC=C519C520OC521=CC=CC=C521C522OC523=CC=CC=C523C524OC525=CC=CC=C525C526OC527=CC=CC=C527C528OC529=CC=CC=C529C530OC53

CRN 101-77-9  
CMF C13 H14 N2




```
L16 ANSWER 4 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN
RN 815600-58-9 REGISTRY
ED Entered STN: 18 Jan 2005
CN 1,5-Naphthalenediamine, polymer with 2,6-bis[[4'-(oxiranylmethoxy)[1,1'-
biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)
MF (C35 H29 N O6 . C10 H10 N2)x
CI PMS
PCT Epoxy resin, Polyether, Polyether
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
```

CRN 815600-49-8  
CMF C35 H29 N O6



CM 2

CRN 2243-62-1  
 CMF C10 H10 N2



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 5 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 815600-57-8 REGISTRY  
 ED Entered STN: 18 Jan 2005  
 CN Benzenamine, 4,4'-methylenebis-, polymer with 2,6-bis[[4'-

10560891


(oxiranylmethoxy) [1,1'-biphenyl]-4-yl]oxy]pyridine (9CI) (CA INDEX NAME)  
MF (C35 H29 N O6 . C13 H14 N2)x  
CI PMS  
PCT Epoxy resin, Polyether, Polyether  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 815600-49-8

CMF C35 H29 N O6

PAGE 1-A




PAGE 2-A



CM 2

CRN 101-77-9


CMF C13 H14 N2



10560891

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 6 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-56-7 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN Pyridine, 2-[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy]-6-[4-(oxiranylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)  
MF C29 H25 N O6  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 7 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-55-6 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN [1,1'-Biphenyl]-4-ol, 4'-[[6-(4-hydroxyphenoxy)-2-pyridinyl]oxy]- (9CI)  
(CA INDEX NAME)  
MF C23 H17 N O4  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL


10560891



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L16 ANSWER 8 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-54-5 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN [1,1'-Biphenyl]-4-ol, 4'-[(6-chloro-2-pyridinyl)oxy] - (9CI) (CA INDEX NAME)  
MF C17 H12 Cl N O2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L16 ANSWER 9 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-53-4 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN Pyrimidine, 4-methyl-2,6-bis[[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]oxy] - (9CI) (CA INDEX NAME)  
MF C35 H30 N2 O6  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 10 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-52-3 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN [1,1'-Biphenyl]-4-ol, 4',4'''-[(6-methyl-2,4-pyrimidinediyl)bis(oxy)]bis-  
(9CI) (CA INDEX NAME)  
MF C29 H22 N2 O4  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L16 ANSWER 11 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-51-2 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN Pyridazine, 3,6-bis[[4'-(oxiran-2-ylmethoxy)[1,1'-biphenyl]-4-yl]oxy] - (9CI)  
(CA INDEX NAME)




10560891

MF C34 H28 N2 O6  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A




PAGE 1-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)



L16 ANSWER 12 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-50-1 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN [1,1'-Biphenyl]-4-ol, 4',4'''-[3,6-pyridazinediylbis(oxy)]bis- (9CI) (CA INDEX NAME)  
MF C28 H20 N2 O4  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 13 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 815600-49-8 REGISTRY  
ED Entered STN: 18 Jan 2005  
CN Pyridine, 2,6-bis[[4'-(oxiran-2-ylmethoxy)[1,1'-biphenyl]-4-yl]oxy]- (9CI) (CA INDEX NAME)  
MF C35 H29 N O6  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 14 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN

RN 30062-98-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN [1,1'-Biphenyl]-4-ol, 4',4'''-[2,6-pyridinediylbis(oxy)]bis- (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

CN 4-Biphenylol, 4',4'''-(2,6-pyridinediylldioxy)di- (8CI)

MF C29 H21 N O4

LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL  
(\*File contains numerically searchable property data)


10560891



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L16 ANSWER 15 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 5424-21-5 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Pyrimidine, 2,4-dichloro-6-methyl- (CA INDEX NAME)  
OTHER NAMES:  
CN 2,4-Dichloro-6-methylpyrimidine  
CN 2,6-Dichloro-4-methylpyrimidine  
CN 6-Methyl-2,4-dichloropyrimidine  
CN NSC 13199  
MF C5 H4 Cl2 N2  
LC STN Files: AGRICOLA, BEILSTEIN\*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,  
CHEMLIST, CSCHM, IFICDB, IFIPAT, IFIUDB, PS, SPECINFO, SYNTHLINE,  
TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

190 REFERENCES IN FILE CA (1907 TO DATE)  
193 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 16 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 2402-78-0 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Pyridine, 2,6-dichloro- (CA INDEX NAME)  
OTHER NAMES:  
CN 2,6-Dichloropyridine  
CN NSC 76606  
MF C5 H3 Cl2 N  
CI COM  
LC STN Files: ANABSTR, AQUIRE, BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS,  
CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHM, DETHERM\*,  
IFICDB, IFIPAT, IFIUDB, PROMT, PS, RTECS\*, SPECINFO, SYNTHLINE,  
TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)


10560891



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

565 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
566 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 17 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 626-16-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Benzene, 1,3-bis(chloromethyl)- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN m-Xylene,  $\alpha,\alpha'$ -dichloro- (7CI, 8CI)  
OTHER NAMES:  
CN  $\alpha,\alpha'$ -Dichloro-m-xylene  
CN 1,3-Bis(chloromethyl)benzene  
CN m-Bis(chloromethyl)benzene  
CN m-Xylene dichloride  
CN m-Xylylene dichloride  
CN NSC 96971  
MF C8 H8 Cl2  
CI COM  
LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,  
CHEMINFORMRX, CHEMLIST, CSCHM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS,  
RTECS\*, SPECINFO, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

265 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
265 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 18 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 141-30-0 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Pyridazine, 3,6-dichloro- (CA INDEX NAME)  
OTHER NAMES:  
CN 3,6-Dichloropyridazine  
CN NSC 54498  
MF C4 H2 Cl2 N2  
CI COM  
LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,

10560891

CHEMINFORMRX, CHEMLIST, CSChem, IFICDB, IFIPAT, IFIUDB, PS, RTECS\*,  
SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
(\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

680 REFERENCES IN FILE CA (1907 TO DATE)  
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
681 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
21 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 19 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN

RN 106-89-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN Oxirane, 2-(chloromethyl)- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Oxirane, (chloromethyl)- (9CI)

CN Propane, 1-chloro-2,3-epoxy- (6CI, 8CI)

OTHER NAMES:

CN (+)-Epichlorohydrin

CN (Chloromethyl)ethylene oxide

CN (Chloromethyl)oxirane

CN (RS)-Epichlorohydrin

CN  $\alpha$ -Epichlorohydrin

CN  $\gamma$ -Chloropropylene oxide

CN 1,2-Epoxy-3-chloropropane

CN 1-Chloro-2,3-epoxypropane

CN 2,3-Epoxypropyl chloride

CN 2-(Chloromethyl)oxirane

CN 3-Chloro-1,2-epoxypropane

CN 3-Chloro-1,2-propylene oxide

CN 3-Chloropropene-1,2-oxide

CN 3-Chloropropylene oxide

CN Chloropropylene oxide

CN dl- $\alpha$ -Epichlorohydrin

CN Epichlorohydrin

CN Glycerol epichlorohydrin

CN Glycidyl chloride

CN J 006

CN NSC 6747

DR 13403-37-7, 9009-12-5, 109351-74-8, 36250-81-4

MF C3 H5 Cl O


CI COM

LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA,  
CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST,  
CHEMSAFE, CIN, CSChem, CSNB, DDFU, DETHERM\*, DRUGU, EMBASE, ENCOMPLIT,  
ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN\*, HSDB\*, IFICDB, IFIPAT,  
IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, PIRA, PROMT, PS, RTECS\*,  
SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VTB  
(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*Enter CHEMLIST File for up-to-date regulatory information)

10560891



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

17384 REFERENCES IN FILE CA (1907 TO DATE)  
4561 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
17416 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L16 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2007 ACS on STN

RN 92-88-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN [1,1'-Biphenyl]-4,4'-diol (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4,4'-Biphenyldiol (8CI)

OTHER NAMES:

CN 4,4'-Biphenol

CN 4,4'-Bisphenol

CN 4,4'-Dihydroxy-1,1'-biphenyl

CN 4,4'-Dihydroxybiphenyl

CN 4,4'-Dihydroxydiphenyl

CN 4,4'-Diphenol

CN 4-(4-Hydroxyphenyl)phenol

CN Antioxidant DOD

CN ASM DOD

CN B 0464

CN BPL

CN BPL (phenol)

CN DOD

CN NSC 8711

CN p,p'-Biphenol

CN p,p'-Dihydroxybiphenyl

CN p,p'-Diphenol

CN p-Dihydroxydiphenyl

CN p-Diphenol

MF C12 H10 O2


CI COM

LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DETHERM\*, EMBASE, GMELIN\*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, PROMT, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

1982 REFERENCES IN FILE CA (1907 TO DATE)

10560891

145 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
1987 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

:end

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

42.15

604.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-2.34

FILE 'STNGUIDE' ENTERED AT 15:10:11 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 11, 2007 (20070511/UP).

=>

Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptadko1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 3 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded  
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data  
NEWS 6 JAN 22 CA/CAPLUS updated with revised CAS roles  
NEWS 7 JAN 22 CA/CAPLUS enhanced with patent applications from India  
NEWS 8 JAN 29 PHAR reloaded with new search and display fields  
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases  
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality  
NEWS 13 FEB 26 MEDLINE reloaded with enhancements  
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field  
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE  
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements  
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases  
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format  
NEWS 19 MAR 16 CASREACT coverage extended  
NEWS 20 MAR 20 MARPAT now updated daily

10560891

NEWS 21 MAR 22 LWPI reloaded  
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements  
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN  
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field  
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records  
NEWS 26 APR 30 CA/CAPplus enhanced with 1870-1889 U.S. patent records  
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN  
NEWS 28 MAY 01 New CAS web site launched  
NEWS 29 MAY 08 CA/CAPplus Indian patent publication number format defined  
NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields  
NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:57:48 ON 16 MAY 2007

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:58:01 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2  
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



10560891


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10560891\_resins2.str



chain nodes :

1 2 3 6 7 8

chain bonds :

1-2 1-8 2-3 3-6 6-7

exact/norm bonds :

1-8

exact bonds :

1-2 2-3 3-6 6-7

Match level :

1:CLASS 2:CLASS 3:CLASS 6:CLASS 7:CLASS 8:Atom

Generic attributes :

2:

Saturation : Unsaturated

3:

Saturation : Unsaturated

Element Count :

Node 2: Limited

C,C6

Node 3: Limited

C,C6

Node 8: Limited

C,C4-5

N,N1-2


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

10560891



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:58:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1146945 TO ITERATE

0.2% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 22883318 TO 22994482  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 15:58:28 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 22943752 TO ITERATE

1.1% PROCESSED 256670 ITERATIONS 0 ANSWERS  
2.0% PROCESSED 452559 ITERATIONS 0 ANSWERS  
2.8% PROCESSED 644587 ITERATIONS 0 ANSWERS  
4.2% PROCESSED 956587 ITERATIONS 2 ANSWERS  
4.4% PROCESSED 1000000 ITERATIONS 2 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.01.15

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 22943752 TO 22943752  
PROJECTED ANSWERS: 25 TO 65

L3 2 SEA SSS FUL L1

=> d scan


L3 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Pyrrolidinepentanamide, 3-[(3'-hydroxy[1,1'-biphenyl]-3-yl)oxy]-  
8,8-dimethyl- $\alpha,\alpha$ -diphenyl-, (3S)-

MF C35 H38 N2 O3

Absolute stereochemistry.

10560891




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 1-Pyrrolidinepentanamide, 3-[(3'-hydroxy[1,1'-biphenyl]-4-yl)oxy]-  
8,8-dimethyl-α,α-diphenyl-, (3S)-  
MF C35 H38 N2 O3

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> 1

1 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.45

173.66

FILE 'STNGUIDE' ENTERED AT 16:00:18 ON 16 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

10560891

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: May 11, 2007 (20070511/UP).

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.24	173.90

FILE 'REGISTRY' ENTERED AT 16:02:24 ON 16 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2  
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10560891\_resin2.str



chain nodes :

1 2 3 6 7 8

chain bonds :

1-2 1-8 2-3 3-6 6-7

exact/norm bonds :

1-8

exact bonds :

1-2 2-3 3-6 6-7

10560891

Match level :

1:CLASS 2:CLASS 3:CLASS 6:CLASS 7:CLASS 8:Atom

Generic attributes :

2:

Saturation : Unsaturated

3:

Saturation : Unsaturated

8:

Saturation : Unsaturated

Element Count :

Node 2: Limited

C,C6

Node 3: Limited

C,C6

Node 8: Limited

C,C4-5


N,N1-2

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 16:02:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1146945 TO ITERATE

0.2% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*  
BATCH \*\*INCOMPLETE\*\*  
PROJECTED ITERATIONS: 22883318 TO 22994482  
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> FIL STNGUIDE

10560891

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.70	176.60

FILE 'STNGUIDE' ENTERED AT 16:05:42 ON 16 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: May 11, 2007 (20070511/UP).

=>

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND  
command can only be used to look at the index in a file which has an  
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of  
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	1.74	178.34

FILE 'REGISTRY' ENTERED AT 16:22:53 ON 16 MAY 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2  
DICTIONARY FILE UPDATES: 15 MAY 2007 HIGHEST RN 934804-03-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\blahblah.str

10560891



chain nodes :

4 5 18

ring nodes :

1 2 3 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

3-4 4-5 11-12

ring bonds :

1-2 1-3 2-3 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

exact/norm bonds :

1-2 1-3 2-3 3-4 4-5

exact bonds :

11-12

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

Match level :

1:Atom 2:Atom 3:Atom 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:Atom

Generic attributes :

18:

Type of Ring System : Monocyclic

Element Count :

Node 18: Limited

C,C4-5

N,N1-2


L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR

10560891



Structure attributes must be viewed using STN Express query preparation.

=> s 16

SAMPLE SEARCH INITIATED 16:23:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7347 TO ITERATE

27.2% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 141802 TO 152078 .

PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s 16 full

FULL SEARCH INITIATED 16:23:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 145946 TO ITERATE

100.0% PROCESSED 145946 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.02

L8 3 SEA SSS FUL L6

=> d scan

L8 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Pyrimidine, 5-octyl-2-[4'-(oxiranylmethoxy)[1,1'-biphenyl]-4-yl]-, (R)-  
(9CI)

MF C27 H32 N2 O2

Absolute stereochemistry.



10560891

ring/chain bonds :

2-5 3-6 11-12

exact/norm bonds :

1-2 1-3 2-5 3-6 11-12

exact bonds :

5-9 9-11

Match level :

1:Atom 2:CLASS 3:CLASS 5:Atom 6:Atom 9:Atom 11:CLASS 12:CLASS

Generic attributes :

5:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

6:

Saturation : Unsaturated

Type of Ring System : Monocyclic

9:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 1: Limited

C,C4-5

N,N1-2

Node 5: Limited

C,C6

Node 6: Limited

C,C6

Node 9: Limited


C,C6

L1 STRUCTURE UPLOADED

=> d l1.

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.


=> s l1

GENERIC GROUP NOT VALID HERE

Generic groups may not be used in these circumstances:

1. Any generic group node (e.g., Hy) in a ring.

10560891




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 2-[4'-[(3-butylloxiranyl)methoxy][1,1'-biphenyl]-4-yl]-5-octyl-, (2S-trans)- (9CI)  
MF C31 H40 N2 O2

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN Pyrimidine, 5-octyl-2-[4'-[(3-propyloxiranyl)methoxy][1,1'-biphenyl]-4-yl]-, (2S-trans)- (9CI)  
MF C30 H38 N2 O2

Absolute stereochemistry.

10560891




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=>

Uploading C:\Program Files\Stnexp\Queries\crud.str



chain nodes :

4 5 18 20

ring nodes :

1 2 3 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

3-4 4-5 11-12 18-20

ring bonds :

1-2 1-3 2-3 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

exact/norm bonds :

1-2 1-3 2-3 3-4 4-5 18-20

exact bonds :

11-12

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17

Match level :

1:Atom 2:Atom 3:Atom 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS

21:Atom

Generic attributes :

18:

Type of Ring System : Monocyclic